



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 35/00, C07H 21/02, C12N 1/00, C12N 1/20, C12N 9/16, C12N 15/00	A1	(11) International Publication Number: <b>WO 00/29000</b> (43) International Publication Date: 25 May 2000 (25.05.2000)
--	----	--

(21) International Application Number: PCT/US99/26871 (22) International Filing Date: 12 November 1999 (12.11.1999) (30) Priority Data: 60/108,324 13 November 1998 (13.11.1998) US (60) Parent Application or Grant LIFE TECHNOLOGIES, INC. [/]; (). GERARD, Gary, F. [/]; (). FLYNN, Elizabeth [/]; (). HU, A-Li, W. [/]; (). ESMOND, Robert, W.; ().	Published
--	-----------

- (54) Title: COMPOSITIONS AND METHODS FOR RECOMBINATIONAL CLONING OF NUCLEIC ACID MOLECULES  
(54) Titre: COMPOSITIONS ET METHODES DE CLONAGE RECOMBINATOIRE DE MOLECULES D'ACIDE NUCLEIQUE

## (57) Abstract

The present invention relates generally to compositions and methods for enhancing recombinational cloning of nucleic acid molecules. In particular, the invention relates to compositions comprising one or more ribosomal proteins and one or more additional protein components required for recombinational cloning. More particularly, the invention relates to such compositions wherein the ribosomal proteins are one or more E. coli ribosomal proteins, still more particularly wherein the ribosomal proteins are selected from the group of E. coli ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, and L23 through L34, and most particularly S20, L27, and S15. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, in vitro and in vivo, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments. The invention also relates to isolated nucleic acid molecules produced by the methods of the invention, to vectors comprising such nucleic acid molecules, and to host cells comprising such nucleic acid molecules and vectors.

## (57) Abrégé

L'invention se rapporte de façon générale à des compositions et méthodes permettant d'améliorer le clonage recombinatoire de molécules d'acide nucléique. Elle concerne en particulier des compositions comprenant une ou plusieurs protéines ribosomales et un ou plusieurs constituants de protéines additionnels nécessaires pour le clonage recombinatoire. L'invention concerne plus particulièrement les compositions dans lesquelles les protéines ribosomales sont une ou plusieurs protéines ribosomales E. coli, qui sont sélectionnées dans le groupe comprenant S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, et L23 à L34, notamment S20, L27, et S15. L'invention porte également sur l'utilisation de ces compositions dans des méthodes de clonage recombinatoire d'acides nucléiques, in vitro et in vivo, afin d'obtenir des molécules d'ADN présentant des caractéristiques et/ou segments d'ADN particuliers. L'invention concerne enfin les molécules d'acide nucléique isolées produites à l'aide des méthodes de l'invention, les vecteurs comprenant ces molécules d'acide nucléique, et à les cellules hôtes comprenant ces molécules d'acide nucléique et ces vecteurs.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 35/00, C12N 15/00, 9/16, 1/20, 1/00, C07H 21/02</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/29000</b> (43) International Publication Date: <b>25 May 2000 (25.05.00)</b>
(21) International Application Number: <b>PCT/US99/26871</b> (22) International Filing Date: <b>12 November 1999 (12.11.99)</b> (30) Priority Data: <b>60/108,324 13 November 1998 (13.11.98) US</b> (71) Applicant: <b>LIFE TECHNOLOGIES, INC. [US/US]; 9800 Medical Center Drive, Rockville, MD 20850 (US).</b> (72) Inventors: <b>GERARD, Gary, F.; 8393 William Drive, Frederick, MD 21704 (US). FLYNN, Elizabeth; 6900 Bugledrum Way, Columbia, MD 21045 (US). HU, A-Li, W.; 4315 Clearbrook Lane, Kensington, MD 20895 (US).</b> (74) Agents: <b>ESMOND, Robert, W. et al.; Sterne, Kessler, Goldstein &amp; Fox P.L.L.C., Suite 600, 1100 New York Avenue, Washington, DC 20005-3934 (US).</b>		(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: <b>COMPOSITIONS AND METHODS FOR RECOMBINATIONAL CLONING OF NUCLEIC ACID MOLECULES</b>			
(57) Abstract <p>The present invention relates generally to compositions and methods for enhancing recombinational cloning of nucleic acid molecules. In particular, the invention relates to compositions comprising one or more ribosomal proteins and one or more additional protein components required for recombinational cloning. More particularly, the invention relates to such compositions wherein the ribosomal proteins are one or more <i>E. coli</i> ribosomal proteins, still more particularly wherein the ribosomal proteins are selected from the group of <i>E. coli</i> ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L20, L21, and L23 through L34, and most particularly S20, L27, and S15. The invention also relates to the use of these compositions in methods for recombinational cloning of nucleic acids, <i>in vitro</i> and <i>in vivo</i>, to provide chimeric DNA molecules that have particular characteristics and/or DNA segments. The invention also relates to isolated nucleic acid molecules produced by the methods of the invention, to vectors comprising such nucleic acid molecules, and to host cells comprising such nucleic acid molecules and vectors.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
RJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Description

5

10

15

20

25

30

35

40

45

50

55



5

## Compositions and Methods for Recombinational Cloning of Nucleic Acid Molecules

10

5

### BACKGROUND OF THE INVENTION

#### *Field of the Invention*

15

10

20

25

30

20

The present invention relates generally to recombinant DNA technology. The invention relates more specifically to compositions and methods for recombinational cloning of nucleic acid molecules using recombination systems. In particular, the invention relates to compositions comprising one or more ribosomal proteins, preferably one or more prokaryotic ribosomal proteins and particularly one or more *E. coli* ribosomal proteins, and one or more additional components required for recombinational cloning (such as one or more recombination proteins), and the use of these compositions in methods of recombinational cloning of nucleic acid molecules. The invention also relates to isolated nucleic acid molecules produced by the methods of the invention, to vectors comprising such nucleic acid molecules, and to host cells comprising such nucleic acid molecules and vectors.

#### *Related Art*

35

##### Site-specific recombinases

25

40

45

30

Site-specific recombinases are proteins that are present in many organisms (e.g. viruses and bacteria) and have been characterized to have both endonuclease and ligase properties. These recombinases (along with associated proteins in some cases) recognize specific sequences of bases in DNA and exchange the DNA segments flanking those segments. The recombinases and associated proteins are collectively referred to as "recombination proteins" (*see, e.g.*, Landy, A., *Current Opinion in Biotechnology* 3:699-707 (1993)).

50

Numerous recombination systems from various organisms have been described. *See, e.g.* Hoess *et al.*, *Nucleic Acids Research* 14(6):2287 (1986);

Abremski *et al.*, *J. Biol. Chem.* 261(1):391 (1986); Campbell, *J. Bacteriol.* 174(23):7495 (1992); Qian *et al.*, *J. Biol. Chem.* 267(11):7794 (1992); Araki *et al.*, *J. Mol. Biol.* 225(1):25 (1992); Maeser and Kahnmann *Mol. Gen. Genet.* 230:170-176 (1991); Esposito *et al.*, *Nucl. Acids Res.* 25(18):3605 (1997).

Many of these belong to the integrase family of recombinases (Argos *et al. EMBO J.* 5:433-440 (1986)). Perhaps the best studied of these are the Integrase/*att* system from bacteriophage  $\lambda$  (Landy, A. *Current Opinions in Genetics and Devel.* 3:699-707 (1993)), the Cre/*loxP* system from bacteriophage P1 (Hoess and Abremski (1990) In *Nucleic Acids and Molecular Biology*, vol. 4. Eds.: Eckstein and Lilley, Berlin-Heidelberg: Springer-Verlag; pp. 90-109), and the FLP/FRT system from the *Saccharomyces cerevisiae* 2  $\mu$  circle plasmid (Broach *et al. Cell* 29:227-234 (1982)).

Backman (U.S. Patent No. 4,673,640) discloses the *in vivo* use of  $\lambda$  recombinase to recombine a protein producing DNA segment by enzymatic site-specific recombination using wild-type recombination sites *attB* and *attP*.

Hasan and Szybalski (*Gene* 56:145-151 (1987)) discloses the use of  $\lambda$  Int recombinase *in vivo* for intramolecular recombination between wild type *attP* and *attB* sites which flank a promoter. Because the orientations of these sites are inverted relative to each other, this causes an irreversible flipping of the promoter region relative to the gene of interest.

Palazzolo *et al. Gene* 88:25-36 (1990), discloses phage lambda vectors having bacteriophage  $\lambda$  arms that contain restriction sites positioned outside a cloned DNA sequence and between wild-type *loxP* sites. Infection of *E. coli* cells that express the Cre recombinase with these phage vectors results in recombination between the *loxP* sites and the *in vivo* excision of the plasmid replicon, including the cloned cDNA.

Pósfai *et al. (Nucl. Acids Res.* 22:2392-2398 (1994)) discloses a method for inserting into genomic DNA partial expression vectors having a selectable marker, flanked by two wild-type FRT recognition sequences. FLP site-specific recombinase as present in the cells is used to integrate the vectors into the

genome at predetermined sites. Under conditions where the replicon is functional, this cloned genomic DNA can be amplified.

Bebec *et al.* (U.S. Patent No. 5,434,066) discloses the use of site-specific recombinases such as Cre for DNA containing two *loxP* sites is used for *in vivo* recombination between the sites.

Boyd (*Nucl. Acids Res.* 21:817-821 (1993)) discloses a method to facilitate the cloning of blunt-ended DNA using conditions that encourage intermolecular ligation to a dephosphorylated vector that contains a wild-type *loxP* site acted upon by a Cre site-specific recombinase present in *E. coli* host cells.

Waterhouse *et al.* (PCT No. 93/19172 and *Nucleic Acids Res.* 21 (9):2265 (1993)) disclose an *in vivo* method where light and heavy chains of a particular antibody were cloned in different phage vectors between *loxP* and *loxP 511* sites and used to transfect new *E. coli* cells. Cre, acting in the host cells on the two parental molecules (one plasmid, one phage), produced four products in equilibrium: two different cointegrates (produced by recombination at either *loxP* or *loxP 511* sites), and two daughter molecules, one of which was the desired product.

In contrast to the other related art, Schlake & Bode (*Biochemistry* 33:12746-12751 (1994)) discloses an *in vivo* method to exchange expression cassettes at defined chromosomal locations, each flanked by a wild type and a spacer-mutated FRT recombination site. A double-reciprocal crossover was mediated in cultured mammalian cells by using this FLP/FRT system for site-specific recombination.

**Transposases.** The family of enzymes, the transposases, has also been used to transfer genetic information between replicons. Transposons are structurally variable, being described as simple or compound, but typically encode the recombinase gene flanked by DNA sequences organized in inverted orientations. Integration of transposons can be random or highly specific. Representatives such as Tn7, which are highly site-specific, have been applied to

the *in vivo* movement of DNA segments between replicons (Lucklow *et al.*, *J. Virol.* 67:4566-4579 (1993)).

Devine and Boeke *Nucl. Acids Res.* 22:3765-3772 (1994), discloses the construction of artificial transposons for the insertion of DNA segments, *in vitro*, into recipient DNA molecules. The system makes use of the integrase of yeast TY1 virus-like particles. The DNA segment of interest is cloned, using standard methods, between the ends of the transposon-like element TY1. In the presence of the TY1 integrase, the resulting element integrates randomly into a second target DNA molecule.

#### DNA cloning

The cloning of DNA segments currently occurs as a daily routine in many research labs and as a prerequisite step in many genetic analyses. The purpose of these clonings is various, however, two general purposes can be considered: (1) the initial cloning of DNA from large DNA or RNA segments (chromosomes, YACs, PCR fragments, mRNA, etc.), done in a relative handful of known vectors such as pUC, pGem, pBlueScript, and (2) the subcloning of these DNA segments into specialized vectors for functional analysis. A great deal of time and effort is expended in the transfer of DNA segments from the initial cloning vectors to the more specialized vectors. This transfer is called subcloning.

The basic methods for cloning have been known for many years and have changed little during that time. A typical cloning protocol is as follows:

- (1) digest the DNA of interest with one or two restriction enzymes;
- (2) gel purify the DNA segment of interest when known;
- (3) prepare the vector by cutting with appropriate restriction enzymes, treating with alkaline phosphatase, gel purify etc., as appropriate;
- (4) ligate the DNA segment to the vector, with appropriate controls to eliminate background of uncut and self-ligated vector;
- (5) introduce the resulting vector into an *E. coli* host cell;

(6) pick selected colonies and grow small cultures overnight;

(7) make DNA minipreps; and

(8) analyze the isolated plasmid on agarose gels (often after diagnostic restriction enzyme digestions) or by PCR.

The specialized vectors used for subcloning DNA segments are functionally diverse. These include but are not limited to: vectors for expressing genes in various organisms; for regulating gene expression; for providing tags to aid in protein purification or to allow tracking of proteins in cells; for modifying the cloned DNA segment (*e.g.*, generating deletions); for the synthesis of probes (*e.g.*, riboprobes); for the preparation of templates for DNA sequencing; for the identification of protein coding regions; for the fusion of various protein-coding regions; to provide large amounts of the DNA of interest, *etc.* It is common that a particular investigation will involve subcloning the DNA segment of interest into several different specialized vectors.

As known in the art, simple subclonings can be done in one day (*e.g.*, the DNA segment is not large and the restriction sites are compatible with those of the subcloning vector). However, many other subclonings can take several weeks, especially those involving unknown sequences, long fragments, toxic genes, unsuitable placement of restriction sites, high backgrounds, impure enzymes, *etc.* Subcloning DNA fragments is thus often viewed as a chore to be done as few times as possible.

Several methods for facilitating the cloning of DNA segments have been described, *e.g.*, as in the following references.

Ferguson, J., *et al. Gene* 16:191 (1981), discloses a family of vectors for subcloning fragments of yeast DNA. The vectors encode kanamycin resistance. Clones of longer yeast DNA segments can be partially digested and ligated into the subcloning vectors. If the original cloning vector conveys resistance to ampicillin, no purification is necessary prior to transformation, since the selection will be for kanamycin.

Hashimoto-Gotoh, T., *et al. Gene* 41:125 (1986), discloses a subcloning vector with unique cloning sites within a streptomycin sensitivity gene; in a

streptomycin-resistant host, only plasmids with inserts or deletions in the dominant sensitivity gene will survive streptomycin selection.

Accordingly, traditional subcloning methods, using restriction enzymes and ligase, are time consuming and relatively unreliable. Considerable labor is expended, and if two or more days later the desired subclone can not be found among the candidate plasmids, the entire process must then be repeated with alternative conditions attempted. Although site specific recombinases have been used to recombine DNA *in vivo*, the successful use of such enzymes *in vitro* was expected to suffer from several problems. For example, the site specificities and efficiencies were expected to differ *in vitro*; topologically-linked products were expected; and the topology of the DNA substrates and recombination proteins was expected to differ significantly *in vitro* (see, e.g., Adams *et al*, *J. Mol. Biol.* 226:661-73 (1992)). Reactions that could go on for many hours *in vivo* were expected to occur in significantly less time *in vitro* before the enzymes became inactive. Multiple DNA recombination products were expected in the biological host used, resulting in unsatisfactory reliability, specificity or efficiency of subcloning. Thus, *in vitro* recombination reactions were not expected to be sufficiently efficient to yield the desired levels of product.

#### Ribosomal Proteins

**Characterization.** *E. coli* ribosomes have some 53 different proteins, 21 associated with the 30S subunit (designated S1 through S21) and 32 associated with the 50S subunit (designated L1 through L34). Generally, the lower the number the higher the molecular weight. With the exception of S1 through S4 and L1 through L4, they contain less than 200 amino acids (molecular weights are less than 20 KDa). The primary amino acid sequence of each protein is known. The three-dimensional structures of S5, S6, S8, S17, L1, L7, L9, L14, and L30 are known. Most of these proteins have a relatively high proportion of the two basic amino acids arginine (arg or R) and lysine (lys or K). This intuitively makes sense if most of the ribosomal proteins are assumed to be RNA binding proteins. Much of what is known about ribosomal proteins has been summarized in a series

of articles in *Annual Reviews of Biochemistry*: 51:155 (1982); 52:35 (1983); 53:75 (1984); 54:507 (1985); 66:679 (1997).

**Enhancement of Yeast Recombination Systems.** The yeast FLP/FRT recombination system requires only the FRT DNA binding site and FLP recombinase to carry out recombination. In contrast, the minimum requirements for carrying out recombination in the  $\lambda$  integrase (Int) system include a recombinase (Int) and DNA sites (*att*), but also IHF protein. IHF is a member of the HU family of small DNA binding proteins. These are basic proteins of 100 amino acids or less that bind to DNA and condense its structure. HU will substitute for IHF in the  $\lambda$  recombination system. While IHF and HU do not stimulate the yeast FLP/FRT recombination system, the *E. coli* ribosomal proteins S3, S4, S5, and L2 do (Bruckner and Cox, *Nucl. Acids Res.* 17:3145-3161 (1989)). The *E. coli* ribosomal proteins that have been shown to stimulate the yeast FLP/FRT recombination system are large, all possessing, with one exception, more than 200 amino acids (Table 1); smaller *E. coli* ribosomal proteins have not been shown to stimulate the FLP/FRT (or any other) recombination system.

TABLE 1

*E. coli* RIBOSOMAL PROTEINS THAT STIMULATE  
YEAST FLP/FRT RECOMBINASE

<i>E. coli</i> Ribosomal Protein	No. of Basic Residues (Percentage of Total)	Total No. of Residues	Molec. Weight
S3	39 (16.8%)	232	25,852
S4	39 (19.2%)	203	23,137
S5	22 (13.3%)	166	17,515
L2	48 (17.8%)	269	29,416

## SUMMARY OF THE INVENTION

The present invention provides compositions and methods for obtaining amplified, chimeric or recombinant nucleic acid molecules using recombinational cloning, *in vitro* or *in vivo*. These methods are highly specific, rapid, and less labor intensive than standard cloning or subcloning techniques. The improved specificity, speed and yields of the present invention facilitates DNA or RNA cloning or subcloning, regulation or exchange useful for any related purpose.

In one embodiment, the present invention relates to compositions for use in cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning, comprising at least one ribosomal protein and at least one recombination protein. In a related aspect, the compositions may comprise more than one ribosomal protein and/or more than one recombination protein. Preferably, prokaryotic ribosomal proteins and prokaryotic recombination proteins are used, although eukaryotic ribosomal proteins and/or eukaryotic recombination proteins may also function in accordance with the invention. According to the invention, the ribosomal proteins used may be basic ribosomal proteins, and may be no larger than about 14 kilodaltons in size.

In certain preferred embodiments, the ribosomal protein may be a prokaryotic ribosomal protein, such as an *Escherichia coli* ribosomal protein, particularly an *E. coli* protein including but not limited to S10, S14, S15, S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31, L32, L33 and L34, and most particularly S20, L27 and/or S15. In related embodiments, the recombination protein for use in the compositions is selected from the group consisting of Int, Cre, FLP, Xis, IHF and HU, and is preferably Int. These compositions of the invention may further comprise one or more nucleic acid molecules, including but not limited to one or more Insert Donor molecules, one or more Vector Donor molecules, one or more cointegrate molecules, one or more Product molecules and one or more Byproduct molecules.



5 The invention also relates generally to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning. In one such aspect, the invention relates to such methods comprising:

10 (a) combining *in vitro* or *in vivo*

5 (i) one or more Insert Donor molecules comprising one or more desired nucleic acid segments flanked by at least two recombination sites, wherein the recombination sites do not substantially recombine with each other;

15 (ii) one or more Vector Donor molecules comprising at least two recombination sites, wherein the recombination sites do not substantially recombine with each other;

20 (iii) at least one recombination protein; and

(iv) at least one ribosomal protein;

25 (b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into one or more of the Vector Donor molecules, thereby producing one or more desired Product nucleic acid molecules;

30 and optionally:

(c) combining *in vitro* or *in vivo*

35 20 (i) one or more of the Product molecules comprising the desired segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;

40 25 (ii) one or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;

45 (iii) at least one recombination protein; and

(iv) at least one ribosomal protein; and

30 (d) incubating the combination formed in step (c) under conditions sufficient to transfer one or more of the desired segments into one

5 or more different Vector Donor molecules, thereby producing one or more different Product molecules.

10 The invention also relates to such methods which further comprise incubating the different Product molecules with one or more different Vector Donor molecules under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules.

15 In a related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

- 20 10 a) combining *in vitro* or *in vivo*
- 25 i) one or more Insert Donor molecules comprising one or more nucleic acid segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
  - 15 ii) two or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
  - 30 iii) at least one recombination protein; and
  - 20 iv) at least one ribosomal protein; and
- 35 b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules, thereby producing two or more different Product molecules.
- 40

25 According to the invention, the one or more ribosomal proteins and the one or more recombination proteins for use in these methods are preferably those prokaryotic and/or eukaryotic ribosomal and recombination proteins described

45 herein for use in the compositions of the invention.

30 In another related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

50

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- (a) combining *in vitro* or *in vivo*
- (i) one or more Insert Donor molecules comprising one or more desired nucleic acid segments flanked by at least two recombination sites, wherein the recombination sites do not substantially recombine with each other;
- (ii) one or more Vector Donor molecules comprising at least two recombination sites, wherein the recombination sites do not substantially recombine with each other; and
- (iii) one or more of the compositions of the invention;
- (b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into one or more of the Vector Donor molecules, thereby producing one or more desired Product nucleic acid molecules;
- and optionally:
- (c) combining *in vitro* or *in vivo*
- (i) one or more of the Product molecules comprising the desired segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
- (ii) one or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other; and
- (iii) one or more of the compositions of the invention; and
- (d) incubating the combination formed in step (c) under conditions sufficient to transfer one or more of the desired segments into one or more different Vector Donor molecules, thereby producing one or more different Product molecules.

In another related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

- 5
- 10
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- a) combining *in vitro* or *in vivo*
    - i) one or more Insert Donor molecules comprising one or more nucleic acid segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
    - ii) two or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other; and
    - iii) one or more of the compositions of the invention; and
  - b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules, thereby producing two or more different Product molecules.

15 In another related aspect, the invention relates to methods for recombinational cloning of one or more desired nucleic acid molecules comprising

- 20
- 25
- 30
- 35
- (a) mixing one or more desired nucleic acid molecules with one or more vectors and with one or more of the compositions of the invention; and
  - (b) incubating the mixture under conditions sufficient to transfer the one or more desired nucleic acid molecules into one or more of the vectors.

40 In another related aspect, the invention relates to methods for enhancement of recombinational cloning of nucleic acid molecules, comprising contacting one or more nucleic acid molecules with one or more ribosomal proteins and one or more recombination proteins, or with one or more compositions of the invention, under conditions favoring the recombinational cloning of the one or more nucleic acid molecules.

45 According to the invention, the Insert Donor molecules and nucleic acid molecules for use in the compositions and methods of the invention may be derived from genomic DNA or cDNA, or may be produced by chemical synthesis

50

55

5 methods. In a related aspect, the Insert Donor molecules may comprise one or more vectors.

10 According to the invention, the Vector Donor molecules for use in the compositions and methods of the invention may comprise at least one Selectable  
5 marker, which may be an antibiotic resistance gene, a tRNA gene, an auxotrophic marker, a toxic gene, a phenotypic marker, an antisense oligonucleotide, a restriction endonuclease, a restriction endonuclease cleavage site, an enzyme  
15 cleavage site, a protein binding site, and a sequence complementary to a PCR primer sequence. In a related aspect, the Vector Donor molecules may comprise one or more eukaryotic vectors or one or more prokaryotic vectors. Eukaryotic  
20 vectors suitable for use in this aspect of the invention may comprise, for example, vectors which propagate and/or replicate in yeast cells, plant cells, fish cells, eukaryotic cells, mammalian cells, and/or insect cells, while suitable prokaryotic  
25 vectors may comprise, for example, vectors which propagate and/or replicate in bacteria of the genera *Escherichia* (most particularly *E. coli*), *Salmonella*, *Bacillus*, *Serratia*, *Streptomyces* or *Pseudomonas*.

30 The invention also relates generally to DNA molecules produced by the methods of the invention, particularly to such DNA molecules which are isolated DNA molecules. The invention also relates to vectors comprising such DNA  
20 molecules, and to host cells comprising such DNA molecules and/or vectors.

35 The invention also relates to kits for use in recombinational cloning of a nucleic acid molecule. In one such aspect, the kits of the invention may comprise one or more containers, particularly wherein the kit contains at least one  
40 ribosomal protein and at least one recombination protein. Such proteins may be contained in separate containers in the kit, or may be combined into a common container or containers. In a related aspect, the kits of the invention may  
25 comprise combinations of different ribosomal proteins and/or combinations of different recombination proteins. Ribosomal proteins and recombination proteins suitable for use in the kits of the invention include, but are not necessarily limited  
45 to, those described in detail herein.  
30  
50  
55

Other preferred embodiments of the present invention will be apparent to one of ordinary skill in light of what is known in the art, the following drawings and description of the invention, and the claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1** depicts one general method of the present invention, wherein the starting (parent) DNA molecules can be circular or linear. The goal is to exchange the new subcloning vector D for the original cloning vector B. It is desirable in one embodiment to select for AD and against all the other molecules, including the Cointegrate. The square and circle are sites of recombination: *e.g.*, *loxP* sites, *att* sites, *etc.* For example, segment D can contain expression signals, new drug markers, new origins of replication, or specialized functions for mapping or sequencing DNA.

**Figure 2** depicts a restriction map for plasmid pHN894. *attP*: *attP* attachment site; 'tet': truncated tetracycline resistance gene; amp:  $\beta$ -lactamase gene.

**Figure 3** depicts a restriction map for plasmid pBB105. *attB*: *attB* attachment site; 'tet': truncated tetracycline resistance gene; amp:  $\beta$ -lactamase gene; ori: *colE1* origin of replication; ROP: replication control site.

**Figure 4** depicts a restriction map for plasmid pHN872. *attL*: *attL* attachment site; 'tet': truncated tetracycline resistance gene; 'amp': truncated  $\beta$ -lactamase gene; ori: *colE1* origin of replication; KmR: kanamycin resistance gene.

**Figure 5** depicts a restriction map for plasmid pHN868. *attR*: *attR* attachment site; 'tet': truncated tetracycline resistance gene; amp:  $\beta$ -lactamase gene; ori: *colE1* origin of replication; ROP: replication control site.

**Figure 6** depicts a restriction map for plasmid pEZ13835. WTattP1: modified *attP* attachment site; WTattP3: modified *attP* attachment site; T1T2: transcription terminators; KmR: kanamycin resistance gene; CmR:

chloramphenicol resistance gene; ccdB: death gene; ori: colE1 origin of replication.

Figure 7 depicts a restriction map for plasmid pEZC7501. attB1: modified *attB* attachment site; attB3: modified *attB* attachment site; GFP: truncated green fluorescent protein gene; T7 P: T7 promoter; SP6 P: SP6 promoter; CMV P: CMV promoter; lacI': lac I promoter; lox p: cre recombination site; small t & poly A: SV40 small tumor antigen intron and poly A signal; fl: fl intergenic region; incA: phage P1 incompatibility locus; Amp:  $\beta$ -lactamase gene; ori: colE1 origin of replication.

Figure 8 depicts a restriction map for plasmid pEZ11104. attL1: modified *attL* attachment site; attL3: modified *attL* attachment site; CmR: chloramphenicol resistance gene; KmR: kanamycin resistance gene; ori: colE1 origin of replication.

Figure 9 depicts a restriction map for plasmid pEZC8402. attR'1: modified *attR* attachment site; attR'3: modified *attR* attachment site; lac I: lac repressor gene; amp:  $\beta$ -lactamase gene; ori: colE1 origin of replication; CmR: chloramphenicol resistance gene; fl: fl intergenic region; ccdB: death gene.

Figure 10 depicts a restriction map for plasmid pTRCN2. Ap:  $\beta$ -lactamase gene; ptrc: trc promoter; laqI<sup>Q</sup>: lac repressor gene; fl'ori: fl intergenic region; ori: colE1 origin of replication.

Figure 11 depicts a restriction map for plasmid pTRCN2INT2. Ap:  $\beta$ -lactamase gene; ptrc: trc promoter; laqI<sup>Q</sup>: lac repressor gene; fl'ori: fl intergenic region; ori: colE1 origin of replication; Int:  $\lambda$  integrase gene.

Figure 12 depicts a restriction map for plasmid pTRCN2XIS1. Ap:  $\beta$ -lactamase gene; ptrc: trc promoter; laqI<sup>Q</sup>: lac repressor gene; fl'ori: fl intergenic region; ori: colE1 origin of replication; xis:  $\lambda$  xis gene.

Figure 13 depicts a restriction map for plasmid pTRCN2S20AA. Ap:  $\beta$ -lactamase gene; ptrc: trc promoter; laqI<sup>Q</sup>: lac repressor gene; fl'ori: fl intergenic region; ori: colE1 origin of replication; rpsT: S20 gene.

5                   **Figure 14** depicts a restriction map for plasmid pET12AS20AA. Ap:  $\beta$ -lactamase gene; ori: colE1 origin of replication; 'rpsT: S20 gene; T7: T7 promoter; T7 term: T7 transcription termination sequence.

10                   **Figure 15** is a photograph of an SDS-PAGE gel of fractions from phosphocellulose column fractionation of proteins not bound by hydroxyapatite. Aliquots (7.5  $\mu$ l) from fractions 13 through 20 of the phosphocellulose column of proteins not bound by hydroxyapatite were analyzed by SDS PAGE. IHF ("IHF A": 0.3  $\mu$ g; "IHF B": 0.5  $\mu$ g) and BenchMark protein standards ("M") were run as references. The bottom of the figure indicates the relative ability of aliquots from the fractions to stimulate Int in an integrative recombination gel assay (-, no stimulation; +, ++, +++, increasing levels of stimulation).

15                   **Figure 16** is a photograph of an SDS-PAGE gel of S20 ribosomal protein purified from a side fraction of a native Int purification. Lanes M: BenchMark protein standards; lanes A through E: 5-, 2-, 2-, 1-, and 1- $\mu$ l aliquots, respectively, of Mono S pool of S20.

20                   **Figure 17** is a photograph of an ethidium bromide-stained gel in an integrative recombination gel assay (*see* Materials and Methods) showing the ability of S20 protein in the Mono S pool (*see* Figure 16) to stimulate Int activity. Lane A: Int plus S20; lane B: Int alone; lane C: Int dilution buffer alone. The slowest migrating band is the recombinant DNA product.

25                   **Figure 18** is a photograph of an SDS-PAGE gel of peak fractions containing integrative recombination stimulatory activity from the Mono S columns described in Materials and Methods section Purification of Stimulatory Proteins from Cells producing Native Int and Results section PART II: Purification and Identification of the Stimulatory Proteins. Phosphocellulose Pool #1 was fractionated on a Mono S column producing two peaks of activity at fraction 18 (1 and 2  $\mu$ l, lanes A and B) and fraction 22 (1 and 2  $\mu$ l, lanes C and D). Phosphocellulose Pool #2 was fractionated in a second run on the same Mono S column producing one peak of activity at fraction 24 (1 and 2  $\mu$ l, lanes F and G). S20 was run in lane E and BenchMark protein standard in lane M.



Figure 19 is a photograph of an ethidium bromide-stained gel in an integrative recombination gel assay (Materials and Methods) showing stimulation of 37 ng of native Int by 900 ng of recombinant S20 (Figure 19), 900 ng of S20 (see Figure 16), and 10 µg of L27 (fraction 18 in Figure 18). Lane A: recombinant S20; lane B: S20; lane C: L27; lane D: Int alone; lane E: no added Int or stimulatory protein.

Figure 20 is a photograph of an SDS-PAGE gel of 2 µg of purified recombinant S20.

Figure 21 is a photograph of an ethidium bromide-stained gel in integrative (lanes A to C) and excisive (lanes D to F) recombination gel assays, showing the recombinase activity of 59 ng of Int-His<sub>6</sub> in the presence of 0 ng (lanes B and E) and 382 ng (lanes C and F) of recombinant S20. All assays also contained 12.5 ng IHF. Excisive recombination assays contained 42 ng Xis-His<sub>6</sub>. The assays analyzed in lanes A and D contained no Int-His<sub>6</sub> or rS20.

## DETAILED DESCRIPTION OF THE INVENTION

### Overview

It has been unexpectedly discovered by the present invention that one or more ribosomal proteins, which may be one or more prokaryotic or eukaryotic ribosomal proteins and particularly one or more *E. coli* ribosomal proteins, may be used to enhance, stimulate, or restore the *in vitro* and *in vivo* recombination activity of recombination systems, which may be prokaryotic or eukaryotic recombination systems, such as the λ Int recombination system. Thus, the invention provides compositions comprising such ribosomal proteins, and methods using such compositions, which are useful in performing reversible and/or repeatable cloning and subcloning reactions to manipulate nucleic acid molecules in order to form chimeric nucleic acids using recombination proteins (e.g., λ Int) and recombination sites. Recombinational cloning according to the present invention thus uses compositions comprising one or more ribosomal proteins, and one or more recombination proteins (which may be site-specific

5 prokaryotic recombination proteins), in combination with recombinant nucleic acid molecules having at least one selected recombination site for moving or exchanging segments of nucleic acid molecules, *in vitro* and *in vivo*.

10 The methods of the invention use recombination reactions to generate chimeric DNA or RNA molecules that have the desired characteristic(s) and/or nucleic acid segment(s). The methods of the invention function such that a nucleic acid molecule of interest may be moved or transferred into any number of vector systems. In accordance with the invention, such transfer to various vector systems may be accomplished separately, sequentially or in mass (e.g. into any number of different vectors in one step). The improved specificity, speed and/or yields of the present invention facilitates DNA or RNA cloning, subcloning, regulation or exchange useful for any related purpose. Such purposes include *in vitro* recombination of DNA or RNA segments and *in vitro* or *in vivo* insertion or modification of transcribed, replicated, isolated or genomic DNA or RNA.

### 30 Definitions

In the description that follows, a number of terms used in recombinant DNA technology are utilized extensively. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

35 **Adapter:** is an oligonucleotide or nucleic acid fragment or segment (preferably DNA) which comprises one or more recombination sites (or portions of such recombination sites) which in accordance with the invention can be added to a circular or linear Insert Donor molecule as well as other nucleic acid molecules described herein. When using portions of recombination sites, the missing portion may be provided by the Insert Donor molecule. Such adapters may be added at any location within a circular or linear molecule, although the adapters are preferably added at or near one or both termini of a linear molecule. Preferably, adapters are positioned to be located on both sides (flanking) a particularly nucleic acid molecule of interest. In accordance with the invention,

5 adapters may be added to nucleic acid molecules of interest by standard  
recombinant techniques (e.g. restriction digest and ligation). For example,  
10 adapters may be added to a circular molecule by first digesting the molecule with  
an appropriate restriction enzyme, adding the adapter at the cleavage site and  
5 reforming the circular molecule which contains the adapter(s) at the site of  
cleavage. Alternatively, adapters may be ligated directly to one or more and  
15 preferably both termini of a linear molecule thereby resulting in linear  
molecule(s) having adapters at one or both termini. In one aspect of the  
invention, adapters may be added to a population of linear molecules, (e.g. a  
10 cDNA library or genomic DNA which has been cleaved or digested) to form a  
20 population of linear molecules containing adapters at one and preferably both  
termini of all or substantial portion of said population.

**Amplification:** refers to any *in vitro* method for increasing a number of  
25 copies of a nucleotide sequence with the use of a polymerase. Nucleic acid  
15 amplification results in the incorporation of nucleotides into a DNA and/or RNA  
molecule or primer thereby forming a new molecule complementary to a  
template. The formed nucleic acid molecule and its template can be used as  
30 templates to synthesize additional nucleic acid molecules. As used herein, one  
amplification reaction may consist of many rounds of replication. DNA  
20 amplification reactions include, for example, polymerase chain reaction (PCR).  
35 One PCR reaction may consist of 5-100 "cycles" of denaturation and synthesis  
of a DNA molecule.

**Byproduct:** is a daughter molecule (a new clone produced after the  
40 second recombination event during the recombinational cloning process) lacking  
25 the segment which is desired to be cloned or subcloned.

**Cointegrate:** is at least one recombination intermediate nucleic acid  
45 molecule of the present invention that contains both parental (starting) molecules.  
It will usually be circular. In some embodiments it can be linear.

**Host:** is any prokaryotic or eukaryotic organism that can be a recipient  
30 of the recombinational cloning Product. A "host," as the term is used herein,  
50 includes prokaryotic or eukaryotic organisms that can be genetically engineered.

For examples of such hosts, see Maniatis *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1982).

**Hybridization:** The terms "hybridization" and "hybridizing" refers to base pairing of two complementary single-stranded nucleic acid molecules (RNA and/or DNA) to give a double stranded molecule. As used herein, two nucleic acid molecules may be hybridized, although the base pairing is not completely complementary. Accordingly, mismatched bases do not prevent hybridization of two nucleic acid molecules provided that appropriate conditions, well known in the art, are used.

**Insert or Inserts:** include the desired nucleic acid segment or a population of nucleic acid segments (segment A of Figure 1) which may be manipulated by the methods of the present invention. Thus, the terms Insert(s) are meant to include a particular nucleic acid (preferably DNA) segment or a population of segments. Such Insert(s) can comprise one or more genes.

**Insert Donor:** is one of the two parental nucleic acid molecules (e.g. RNA or DNA) of the present invention which carries the Insert. The Insert Donor molecule comprises the Insert flanked on both sides with recombination sites. The Insert Donor can be linear or circular. In one embodiment of the invention, the Insert Donor is a circular DNA molecule and further comprises a cloning vector sequence outside of the recombination signals (see Figure 1). When a population of Inserts or population of nucleic acid segments are used to make the Insert Donor, a population of Insert Donors result and may be used in accordance with the invention.

**Library:** refers to a collection of nucleic acid molecules (circular or linear). In one preferred embodiment, a library is representative of all or a significant portion of the DNA content of an organism (a "genomic" library), or a set of nucleic acid molecules representative of all or a significant portion of the expressed genes (a cDNA library) in a cell, tissue, organ or organism. A library may also comprise random sequences made by *de novo* synthesis, mutagenesis of one or more sequences and the like. Such libraries may or may not be contained in one or more vectors.

**Nucleotide:** refers to a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid sequence (DNA and RNA). The term nucleotide includes ribonucleoside triphosphates ATP, UTP, CTG, GTP and deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, [ $\alpha$ S]dATP, 7-deaza-dGTP and 7-deaza-dATP. The term nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrated examples of dideoxyribonucleoside triphosphates include, but are not limited to, ddATP, ddCTP, ddGTP, ddITP, and ddTTP. According to the present invention, a "nucleotide" may be unlabeled or detectably labeled by well known techniques. Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels.

**Oligonucleotide:** refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are joined by a phosphodiester bond between the 3' position of the deoxyribose or ribose of one nucleotide and the 5' position of the deoxyribose or ribose of the adjacent nucleotide.

**Primer:** refers to a single stranded or double stranded oligonucleotide that is extended by covalent bonding of nucleotide monomers during amplification or polymerization of a nucleic acid molecule (e.g. a DNA molecule). In a preferred aspect, the primer comprises one or more recombination sites or portions of such recombination sites. Portions of recombination sites comprise at least 2 bases, at least 5 bases, at least 10 bases or at least 20 bases of the recombination sites of interest. When using portions of recombination sites, the missing portion of the recombination site may be provided by the newly synthesized nucleic acid molecule. Such recombination sites may be located within and/or at one or both termini of the primer. Preferably, additional sequences are added to the primer adjacent to the recombination site(s) to enhance or improve recombination and/or to stabilize the recombination site during recombination. Such stabilization sequences may be any sequences (preferably G/C rich sequences) of any length. Preferably, such

sequences range in size from 1 to about 1000 bases, 1 to about 500 bases, and 1 to about 100 bases, 1 to about 60 bases, 1 to about 25, 1 to about 10, 2 to about 10 and preferably about 4 bases. Preferably, such sequences are greater than 1 base in length and preferably greater than 2 bases in length.

**Product:** is one the desired daughter molecules comprising the *A* and *D* sequences which is produced after the second recombination event during the recombinational cloning process (see Figure 1). The Product contains the nucleic acid which was to be cloned or subcloned. In accordance with the invention, when a population of Insert Donors are used, the resulting population of Product molecules will contain all or a portion of the population of Inserts of the Insert Donors and preferably will contain a representative population of the original molecules of the Insert Donors.

**Promoter:** is a DNA sequence generally described as the 5'-region of a gene, located proximal to the start codon. The transcription of an adjacent DNA segment is initiated at the promoter region. A repressible promoter's rate of transcription decreases in response to a repressing agent. An inducible promoter's rate of transcription increases in response to an inducing agent. A constitutive promoter's rate of transcription is not specifically regulated, though it can vary under the influence of general metabolic conditions.

**Recognition sequence:** Recognition sequences are particular sequences which a protein, chemical compound, DNA, or RNA molecule (*e.g.*, restriction endonuclease, a modification methylase, or a recombinase) recognizes and binds. In the present invention, a recognition sequence will usually refer to a recombination site. For example, the recognition sequence for Cre recombinase is *loxP* which is a 34 base pair sequence comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence. See Figure 1 of Sauer, B., *Current Opinion in Biotechnology* 5:521-527 (1994). Other examples of recognition sequences are the *attB*, *attP*, *attL*, and *attR* sequences which are recognized by the recombinase enzyme  $\lambda$  Integrase. *attB* is an approximately 25 base pair sequence containing two 9 base pair core-type Int binding sites and a 7 base pair overlap region. *attP* is an

approximately 240 base pair sequence containing core-type Int binding sites and arm-type Int binding sites as well as sites for auxiliary proteins integration host factor (IHF), FIS, and excisionase (Xis). See Landy, *Current Opinion in Biotechnology* 3:699-707 (1993). Such sites may also be engineered according to the present invention to enhance production of products in the methods of the invention. When such engineered sites lack the P1 or H1 domains to make the recombination reactions irreversible (e.g., attR or attP), such sites may be designated attR' or attP' to show that the domains of these sites have been modified in some way.

**Recombinase:** is a type of recombination protein which catalyzes the exchange of DNA segments at specific recombination sites.

**Recombinational Cloning:** is a method described herein, whereby segments of nucleic acid molecules or populations of such molecules are exchanged, inserted, replaced, substituted or modified, *in vitro* or *in vivo*.

**Recombination proteins:** include excisive or integrative proteins, enzymes, co-factors or associated proteins that are involved in recombination reactions involving one or more recombination sites. See, Landy (1994), *infra*.

**Repression cassette:** is a nucleic acid segment that contains a repressor of a Selectable marker present in the subcloning vector.

**Ribosomal protein:** is a polypeptide, protein, or a functional fragment, mutant, or derivative thereof, that is a constituent of a subunit of a ribosome. According to the invention, the ribosome may be a prokaryotic or eukaryotic ribosome, and is preferably a prokaryotic ribosome, particularly an *E. coli* ribosome, comprising a 30S and a 50S subunit. By a "functional" fragment, mutant, or derivative thereof is meant a fragment, mutant, or derivative of a native ribosomal protein that has substantially the same biological activity as the corresponding native ribosomal protein in stimulating a recombination system such as the  $\lambda$  Int recombination system.

**Selectable marker:** is a DNA segment that allows one to select for or against a molecule or a cell that contains it, often under particular conditions. These markers can encode an activity, such as, but not limited to, production of

RNA, peptide, or protein, or can provide a binding site for RNA, peptides, proteins, inorganic and organic compounds or compositions and the like. Examples of Selectable markers include but are not limited to: (1) DNA segments that encode products which provide resistance against otherwise toxic compounds (*e.g.*, antibiotics); (2) DNA segments that encode products which are otherwise lacking in the recipient cell (*e.g.*, tRNA genes, auxotrophic markers); (3) DNA segments that encode products which suppress the activity of a gene product; (4) DNA segments that encode products which can be readily identified (*e.g.*, phenotypic markers such as  $\beta$ -galactosidase, green fluorescent protein (GFP), and cell surface proteins); (5) DNA segments that bind products which are otherwise detrimental to cell survival and/or function; (6) DNA segments that otherwise inhibit the activity of any of the DNA segments described in Nos. 1-5 above (*e.g.*, antisense oligonucleotides); (7) DNA segments that bind products that modify a substrate (*e.g.* restriction endonucleases); (8) DNA segments that can be used to isolate or identify a desired molecule (*e.g.* specific protein binding sites); (9) DNA segments that encode a specific nucleotide sequence which can be otherwise non-functional (*e.g.*, for PCR amplification of subpopulations of molecules); (10) DNA segments, which when absent, directly or indirectly confer resistance or sensitivity to particular compounds; and/or (11) DNA segments that encode products which are toxic in recipient cells.

**Selection scheme:** is any method which allows selection, enrichment, or identification of a desired Product or Product(s) from a mixture containing the Insert Donor, Vector Donor, any intermediates (*e.g.* a Cointegrate), and/or Byproducts. The selection schemes of one preferred embodiment have at least two components that are either linked or unlinked during recombinational cloning. One component is a Selectable marker. The other component controls the expression *in vitro* or *in vivo* of the Selectable marker, or survival of the cell harboring the plasmid carrying the Selectable marker. Generally, this controlling element will be a repressor or inducer of the Selectable marker, but other means for controlling expression of the Selectable marker can be used. Whether a repressor or activator is used will depend on whether the marker is for a positive



5 or negative selection, and the exact arrangement of the various DNA segments,  
as will be readily apparent to those skilled in the art. A preferred requirement is  
10 that the selection scheme results in selection of or enrichment for only one or  
more desired Products. As defined herein, selecting for a DNA molecule includes  
5 (a) selecting or enriching for the presence of the desired DNA molecule, and (b)  
selecting or enriching against the presence of DNA molecules that are not the  
15 desired DNA molecule.

In one embodiment, the selection schemes (which can be carried out in  
reverse) will take one of three forms, which will be discussed in terms of  
10 Figure 1. The first, exemplified herein with a Selectable marker and a repressor  
therefore, selects for molecules having segment *D* and lacking segment *C*. The  
20 second selects against molecules having segment *C* and for molecules having  
segment *D*. Possible embodiments of the second form would have a DNA  
25 segment carrying a gene toxic to cells into which the *in vitro* reaction products are  
to be introduced. A toxic gene can be a DNA that is expressed as a toxic gene  
15 product (a toxic protein or RNA), or can be toxic in and of itself. (In the latter  
case, the toxic gene is understood to carry its classical definition of "heritable  
30 trait".)

Examples of such toxic gene products are well known in the art, and  
20 include, but are not limited to, restriction endonucleases (*e.g.*, *DpnI*), apoptosis-  
35 related genes (*e.g.* ASK1 or members of the *bcl-2/ced-9* family), retroviral genes  
including those of the human immunodeficiency virus (HIV), defensins such as  
NP-1, inverted repeats or paired palindromic DNA sequences, bacteriophage lytic  
40 genes such as those from  $\phi$ X174 or bacteriophage T4; antibiotic sensitivity genes  
25 such as *rpsL*, antimicrobial sensitivity genes such as *pheS*, plasmid killer genes,  
eukaryotic transcriptional vector genes that produce a gene product toxic to  
bacteria, such as GATA-1, and genes that kill hosts in the absence of a  
45 suppressing function, *e.g.*, *kicB* or *ccdB*. A toxic gene can alternatively be  
selectable *in vitro*, *e.g.*, a restriction site.

30 Many genes coding for restriction endonucleases operably linked to  
inducible promoters are known, and may be used in the present invention. *See*,

5 e.g. U.S. Patent Nos. 4,960,707 (*DpnI* and *DpnII*); 5,000,333, 5,082,784 and  
5,192,675 (*KpnI*); 5,147,800 (*NgoAIII* and *NgoAI*); 5,179,015 (*FspI* and *HaeIII*):  
10 5,200,333 (*HaeII* and *TaqI*); 5,248,605 (*HpaII*); 5,312,746 (*ClaI*); 5,231,021 and  
5,304,480 (*XhoI* and *XhoII*); 5,334,526 (*AluI*); 5,470,740 (*NsiI*); 5,534,428  
5 (*SstI/SacI*); 5,202,248 (*NcoI*); 5,139,942 (*NdeI*); and 5,098,839 (*PacI*). *See also*  
Wilson, G.G., *Nucl. Acids Res.* 19:2539-2566 (1991); and Lunnen, K.D., *et al.*,  
15 *Gene* 74:25-32 (1988).

In the second form, segment *D* carries a Selectable marker. The toxic  
gene would eliminate transformants harboring the Vector Donor, Cointegrate, and  
10 Byproduct molecules, while the Selectable marker can be used to select for cells  
20 containing the Product and against cells harboring only the Insert Donor.

The third form selects for cells that have both segments *A* and *D* in *cis* on  
the same molecule, but not for cells that have both segments in *trans* on different  
25 molecules. This could be embodied by a Selectable marker that is split into two  
15 inactive fragments, one each on segments *A* and *D*.

The fragments are so arranged relative to the recombination sites that  
when the segments are brought together by the recombination event, they  
30 reconstitute a functional Selectable marker. For example, the recombinational  
event can link a promoter with a structural gene, can link two fragments of a  
structural gene, or can link genes that encode a heterodimeric gene product  
20 needed for survival, or can link portions of a replicon.  
35

**Site-specific recombinase:** is a type of recombinase which typically has  
at least the following four activities (or combinations thereof): (1) recognition of  
40 one or two specific nucleic acid sequences; (2) cleavage of said sequence or  
sequences; (3) topoisomerase activity involved in strand exchange; and (4) ligase  
25 activity to reseal the cleaved strands of nucleic acid. *See* Sauer, B., *Current*  
*Opinions in Biotechnology* 5:521-527 (1994). Conservative site-specific  
45 recombination is distinguished from homologous recombination and transposition  
by a high degree of specificity for both partners. The strand exchange mechanism  
30 involves the cleavage and rejoining of specific DNA sequences in the absence of  
DNA synthesis (Landy, A. (1989) *Ann. Rev. Biochem.* 58:913-949).  
50

5                   **Subcloning vector:** is a cloning vector comprising a circular or linear  
nucleic acid molecule which includes preferably an appropriate replicon. In the  
10                   present invention, the subcloning vector (segment *D* in Figure 1) can also contain  
functional and/or regulatory elements that are desired to be incorporated into the  
5                   final product to act upon or with the cloned DNA Insert (segment *A* in Figure 1).  
The subcloning vector can also contain a Selectable marker (preferably DNA).

15                   **Template:** refers to double stranded or single stranded nucleic acid  
molecules which are to be amplified, synthesized or sequenced. In the case of  
double stranded molecules, denaturation of its strands to form a first and a second  
10                   strand is preferably performed before these molecules will be amplified,  
20                   synthesized or sequenced, or the double stranded molecule may be used directly  
as a template. For single stranded templates, a primer complementary to a  
portion of the template is hybridized under appropriate conditions and one or  
25                   more polypeptides having polymerase activity (e.g. DNA polymerases and/or  
reverse transcriptases) may then synthesize a nucleic acid molecule  
15                   complementary to all or a portion of said template. Alternatively, for double  
stranded templates, one or more promoters may be used in combination with one  
30                   or more polymerases to make nucleic acid molecules complementary to all or a  
portion of the template. The newly synthesized molecules, according to the  
20                   invention, may be equal or shorter in length than the original template.  
35                   Additionally, a population of nucleic acid templates may be used during synthesis  
or amplification to produce a population of nucleic acid molecules typically  
representative of the original template population.

40                   **Vector:** is a nucleic acid molecule (preferably DNA) that provides a  
25                   useful biological or biochemical property to an Insert. Examples include  
plasmids, phages, autonomously replicating sequences (ARS), centromeres, and  
45                   other sequences which are able to replicate or be replicated *in vitro* or in a host  
cell, or to convey a desired nucleic acid segment to a desired location within a  
host cell. A Vector can have one or more restriction endonuclease recognition  
30                   sites at which the sequences can be cut in a determinable fashion without loss of  
50                   an essential biological function of the vector, and into which a nucleic acid

5 fragment can be spliced in order to bring about its replication and cloning. Vectors can further provide primer sites, *e.g.*, for PCR, transcriptional and/or translational initiation and/or regulation sites, recombinational signals, replicons, 10 Selectable markers, *etc.* Clearly, methods of inserting a desired nucleic acid fragment which do not require the use of homologous recombination, transpositions or restriction enzymes (such as, but not limited to, UDG cloning of PCR fragments (U.S. Patent No. 5,334,575, entirely incorporated herein by 15 reference), T:A cloning, and the like) can also be applied to clone a fragment into a cloning vector to be used according to the present invention. The cloning vector can further contain one or more selectable markers suitable for use in the 20 identification of cells transformed with the cloning vector.

**Vector Donor:** is one of the two parental nucleic acid molecules (*e.g.* RNA or DNA) of the present invention which carries the DNA segments 25 comprising the DNA vector which is to become part of the desired Product. The Vector Donor comprises a subcloning vector *D* (or it can be called the cloning vector if the Insert Donor does not already contain a cloning vector) and a 30 segment *C* flanked by recombination sites (see Figure 1). Segments *C* and/or *D* can contain elements that contribute to selection for the desired Product daughter molecule, as described above for selection schemes. The recombination signals 35 can be the same or different, and can be acted upon by the same or different recombinases. In addition, the Vector Donor can be linear or circular.

Other terms used in the fields of recombinant DNA technology and molecular and cell biology as used herein will be generally understood by one of 40 ordinary skill in the applicable arts.

#### 25 Recombination Schemes

One general scheme for an *in vitro* or *in vivo* method of the invention is 45 shown in Figure 1, where the Insert Donor and the Vector Donor can be either circular or linear DNA, but is shown as circular. Vector *D* is exchanged for the original cloning vector *B*. The Insert Donor need not comprise a vector. The 30 method of the invention allows the Inserts *A* to be transferred into any number of 50

5 vectors. According to the invention, the Inserts may be transferred to a particular  
Vector or may be transferred to a number of vectors in one step. Additionally, the  
10 Inserts may be transferred to any number of vectors sequentially, for example, by  
using the Product DNA molecule as the Insert Donor in combination with a  
5 different Vector Donor. The nucleic acid molecule of interest may be transferred  
into a new vector thereby producing a new Product DNA molecule. The new  
15 Product DNA molecule may then be used as starting material to transfer the  
nucleic acid molecule of interest into a new vector. Such sequential transfers can  
be performed a number of times in any number of different vectors. Thus the  
20 invention allows for cloning or subcloning nucleic acid molecules and because  
of the ease and simplicity, these methods are particularly suited for high through-  
put applications. In accordance with the invention, it is desirable to select for the  
daughter molecule containing elements *A* and *D* and against other molecules,  
25 including one or more Cointegrate(s). The square and circle are different sets of  
recombination sites (e.g., *lox* sites or *att* sites). Segment *A* or *D* can contain at  
15 least one Selection Marker, expression signals, origins of replication, or  
specialized functions for detecting, selecting, expressing, mapping or sequencing  
DNA, where *D* is used in this example. This scheme can also be reversed  
30 according to the present invention, as described herein. The resulting product of  
the reverse reaction (e.g. the Insert Donor) may then be used in combination with  
20 one or a number of vectors to produce new product molecules in which the Inserts  
35 are contained by any number of vectors.

40 Examples of desired DNA segments that can be part of Element *A* or *D*  
include, but are not limited to, PCR products, large DNA segments, genomic  
25 clones or fragments, cDNA clones or fragments, functional elements, *etc.*, and  
genes or partial genes, which encode useful nucleic acids or proteins. Moreover,  
the recombinational cloning of the present invention can be used to make *ex vivo*  
45 and *in vivo* gene transfer vehicles for protein expression (native or fusion  
proteins) and/or gene therapy.

30 In Figure 1, the scheme provides the desired Product as containing *A* and  
50 Vector *D*, as follows. The Insert Donor (containing *A* and *B*) is first recombined

5 at the square recombination sites by recombination proteins, with the Vector Donor (containing *C* and *D*), to form a Co-integrate having each of A-D-C-B. Next, recombination occurs at the circle recombination sites to form Product DNA (*A* and *D*) and Byproduct DNA *C* and *B*). However, if desired, two or more  
10 different Co-integrates can be formed to generate two or more Products.

Recombinational cloning using nucleic acid molecules comprising engineered recombination sites, and the materials and methods by which this technique may be accomplished, have been described in detail in U.S. Application Nos. 08/486,139, filed June 7, 1995 (now abandoned), 08/663,002,  
15 filed June 7, 1996 (now U.S. Patent No. 5,888,732), 09/005,476, filed January 12, 1998, 60/065,930, filed October 24, 1997, 09/177,387, filed October 23, 1998, 60/122,389, filed March 2, 1999, 60/122,392, filed March 22, 1999, 60/126,049, filed March 23, 1999, and 60/136,744, filed May 28, 1999. The disclosures of all of the above-referenced patent applications  
20 are incorporated herein by reference in their entireties for their relevant teachings.

### 30 Compositions

By the present invention, compositions are provided that may be used in recombinational cloning of nucleic acid molecules or segments thereof. Compositions of the invention may comprise mixtures of at least one ribosomal  
20 protein and at least one recombination protein, suitable for use in the recombinational cloning of nucleic acid molecules. The compositions of the invention may comprise two or more, three or more, four or more, five or more, etc., ribosomal proteins, recombination proteins, or combinations thereof. In  
35 related embodiments, the compositions may further comprise one or more additional components, such as one or more nucleic acid molecules (including, but not limited to, one or more Insert Donor molecules, one or more Vector Donor molecules, one or more cointegrate molecules, one or more Product  
40 molecules and one or more Byproduct molecules), one or more buffer salts, and/or other reagents which may be used in recombinational cloning of nucleic acid molecules. In related aspects, the ribosomal proteins, recombination  
25 30 35 40 45 50 55

5 proteins, and/or compositions of the invention may contain one or more  
stabilizing compounds (e.g., glycerol, serum albumin or gelatin) that are  
10 traditionally included in stock reagent solutions. Suitable amounts of such  
stabilizing compounds will be familiar to one of ordinary skill in the art, or may  
5 be easily determined using only routine experimentation. For example, glycerol  
may be used in the compositions of the invention at a concentration (vol/vol) of  
15 about 5%-75%, about 10%-65%, about 15%-60%, about 20%-55%, about 25%-  
50%, or about 50%. In an additional related aspect, the invention provides these  
compositions in ready-to-use concentrations, obviating the time-consuming  
20 dilution and pre-mixing steps necessary with previously available solutions.

20 *Ribosomal Proteins.* The one or more ribosomal proteins used in the  
present compositions may be basic ribosomal proteins. By a "basic" ribosomal  
protein is meant a ribosomal protein that comprises a relatively high percentage  
25 (i.e., ranging from about 15-50%) of basic amino acid residues, particularly  
arginine and lysine. The ribosomal proteins used in the compositions and  
15 methods of the invention preferably are no larger than about 14 kilodaltons (kD)  
in size, and more preferably are about 5 kD to about 14 kD, about 6 kD to about  
30 13 kD, about 7 kD to about 12 kD, or about 8 kD to about 12 kD, in size.

According to the invention, the one or more ribosomal proteins may be one or  
20 more prokaryotic ribosomal proteins (e.g., one or more bacterial ribosomal  
35 proteins) or one or more eukaryotic ribosomal proteins, e.g., one or more  
ribosomal proteins of animals (such as mammals (including humans), fish, birds,  
reptiles, amphibians, monotremes, and the like), fungi, plants, and the like. In  
40 certain compositions, the ribosomal proteins may be one or more prokaryotic  
25 ribosomal proteins, particularly one or more ribosomal proteins obtained from  
bacteria including, but not limited to, those of the genera *Escherichia*, *Serratia*,  
*Salmonella*, *Pseudomonas*, *Bacillus*, *Streptomyces*, *Staphylococcus*,  
45 *Streptococcus*, or other gram positive or gram negative bacteria.

In particularly preferred compositions of the invention, the ribosomal  
30 proteins may be one or more *Escherichia coli* ribosomal proteins. Particularly  
50 preferred such *E. coli* ribosomal proteins for use in the compositions and methods

of the invention include, but are not limited to, S10, S14, S15, S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31, L32, L33 and L34. Most preferred *E. coli* ribosomal proteins for use in the compositions and methods of the invention are S20, L27 and S15. Corresponding ribosomal proteins from other sources, including prokaryotic or eukaryotic sources, may be used in accordance with the invention. Such corresponding ribosomal proteins preferably correspond (in structure, size, biochemistry, and/or function) to the *E. coli* ribosomal proteins described herein.

Sources and methods for production and isolation of ribosomal proteins, particularly prokaryotic ribosomal proteins, are described in detail in Example 1 below. In addition, information on sources and isolation of prokaryotic and eukaryotic ribosomal proteins may be found in *Ann. Rev. Biochem.* 51:155 (1982); *Ann. Rev. Biochem.* 52:35 (1983); *Ann. Rev. Biochem.* 53:75 (1984); *Ann. Rev. Biochem.* 54:507 (1985); *Ann. Rev. Biochem.* 66:679 (1997); and Bruckner and Cox, *Nucl. Acids Res.* 17(8):3145-3161 (1989).

The amount of one or more ribosomal proteins which is optimal for use in the compositions and methods of the present invention to drive the recombination reaction can be determined using known assays. Specifically, a titration assay may be used to determine the appropriate amount of a purified ribosomal protein, or the appropriate amount of an extract. Such assays are described in detail in the Examples below. In certain embodiments, for example, the compositions may comprise an effective amount of the *E. coli* ribosomal proteins S20 or S15, for example at a concentration range of about 1 ng to about 2500 ng, about 2 ng to about 2000 ng, about 5 ng to about 1500 ng, about 10 ng to about 1500 ng, about 25 ng to about 1500 ng, about 50 ng to about 1500 ng, about 100 ng to about 1500 ng, about 250 ng to about 1500 ng, about 300 ng to about 1500 ng, about 500 ng to about 1500 ng, about 500 ng to about 1250 ng, or about 625 ng to about 1250 ng. In other embodiments, the compositions may comprise the *E. coli* ribosomal protein L27, at a concentration of, for example, about 1,000 ng to about 50,000 ng, about 2,000 ng to about 40,000 ng, about 5,000 ng to about 30,000 ng, about 10,000 ng to about 25,000 ng, about 10,000



5 ng to about 20,000 ng, or about 10,000 ng. Of course, other concentration ranges  
for S20, S15, or L27, or other suitable prokaryotic or eukaryotic ribosomal  
10 proteins that may be used in the present compositions, may be determined by one  
of ordinary skill without undue experimentation by carrying out a titration assay  
5 as noted above and as described in detail in the Examples below.

*Recombination Proteins.* In the compositions and methods of the present  
15 invention, the exchange of DNA segments is achieved by the use of  
recombination proteins, including recombinases and associated co-factors and  
proteins. The one or more recombination proteins for use in the compositions  
20 may be any recombination protein, including any prokaryotic or eukaryotic  
recombination protein, that is suitable for use in recombinational cloning of  
nucleic acid molecules. Examples of such recombination proteins include, but are  
not limited to:

25 *Cre:* A prokaryotic recombination protein from bacteriophage P1  
(Abremski and Hoess, *J. Biol. Chem.* 259(3):1509-1514 (1984)) catalyzes the  
15 exchange (i.e., causes recombination) between 34 bp DNA sequences called *loxP*  
(locus of crossover) sites (See Hoess *et al.*, *Nucl. Acids Res.* 14(5):2287 (1986)).  
30 *Cre* is available commercially (Novagen, Catalog No. 69247-1). Recombination  
mediated by *Cre* is freely reversible. From thermodynamic considerations it is  
20 not surprising that *Cre*-mediated integration (recombination between two  
35 molecules to form one molecule) is much less efficient than *Cre*-mediated  
excision (recombination between two *loxP* sites in the same molecule to form two  
daughter molecules). *Cre* works in simple buffers with either magnesium or  
40 spermidine as a cofactor, as is well known in the art. The DNA substrates can be  
25 either linear or supercoiled. A number of mutant *loxP* sites have been described  
(Hoess *et al.*, *supra*). One of these, *loxP 511*, recombines with another *loxP 511*  
45 site, but will not recombine with a *loxP* site.

*Integrase:* A prokaryotic recombination protein from bacteriophage  
50 lambda that mediates the integration of the lambda genome into the *E. coli*  
30 chromosome. The bacteriophage  $\lambda$  Int recombinational proteins promote  
recombination between its substrate *att* sites as part of the formation or induction

5 of a lysogenic state. Reversibility of the recombination reactions results from two  
independent pathways for integrative and excisive recombination. Each pathway  
10 uses a unique, but overlapping, set of the 15 protein binding sites that comprise  
*att* site DNAs. Cooperative and competitive interactions involving four proteins  
5 (Int, Xis, IHF and FIS) determine the direction of recombination.

Integrative recombination involves the Int and IHF proteins and sites *attP*  
15 (240 bp) and *attB* (25 bp). Recombination results in the formation of two new  
sites: *attL* and *attR*. Excisive recombination requires Int, IHF, and Xis, and sites  
*attL* and *attR* to generate *attP* and *attB*. Under certain conditions, FIS stimulates  
20 excisive recombination. In addition to these normal reactions, it should be  
appreciated that *attP* and *attB*, when placed on the same molecule, can promote  
*excisive* recombination to generate two excision products, one with *attL* and one  
with *attR*. Similarly, intermolecular recombination between molecules containing  
25 *attL* and *attR*, in the presence of Int, IHF and Xis, can result in *integrative*  
recombination and the generation of *attP* and *attB*. Hence, by flanking DNA  
15 segments with appropriate combinations of engineered *att* sites, in the presence  
of the appropriate recombination proteins, one can direct excisive or integrative  
30 recombination, as reverse reactions of each other.

Each of the *att* sites contains a 15 bp core sequence; individual sequence  
20 elements of functional significance lie within, outside, and across the boundaries  
of this common core (Landy, A., *Ann. Rev. Biochem.* 58:913 (1989)). Efficient  
35 recombination between the various *att* sites requires that the sequence of the  
central common region be identical between the recombining partners, however,  
40 the exact sequence is now found to be modifiable. Consequently, derivatives of  
the *att* site with changes within the core are now discovered to recombine as least  
25 as efficiently as the native core sequences.

Integrase acts to recombine the *attP* site on bacteriophage lambda (about  
45 240 bp) with the *attB* site on the *E. coli* genome (about 25 bp) (Weisberg, R.A.  
and Landy, A. in *Lambda II*, p. 211 (1983), Cold Spring Harbor Laboratory)), to  
30 produce the integrated lambda genome flanked by *attL* (about 100 bp) and *attR*  
50 (about 160 bp) sites. In the absence of Xis (see below), this reaction is essentially

irreversible. The integration reaction mediated by integrase and IHF works *in vitro*, with simple buffer containing spermidine. Integrase can be obtained as described by Nash, H.A., *Methods of Enzymology* 100:210-216 (1983). IHF can be obtained as described by Filutowicz, M., *et al.*, *Gene* 147:149-150 (1994).

Numerous recombination systems from various organisms can also be used, based on the teaching and guidance provided herein. *See, e.g.*, Hoess *et al.*, *Nucleic Acids Research* 14(6):2287 (1986); Abremski *et al.*, *J. Biol. Chem.* 261(1):391 (1986); Campbell, *J. Bacteriol.* 174(23):7495 (1992); Qian *et al.*, *J. Biol. Chem.* 267(11):7794 (1992); Araki *et al.*, *J. Mol. Biol.* 225(1):25 (1992)). Many of these belong to the integrase family of recombinases (Argos *et al.* *EMBO J.* 5:433-440 (1986)). Perhaps the best studied of these are the Integrase/*att* system from bacteriophage  $\lambda$  (Landy, A. (1993) *Current Opinions in Genetics and Devel.* 3:699-707), the Cre/*loxP* system from bacteriophage P1 (Hoess and Abremski (1990) In *Nucleic Acids and Molecular Biology*, vol. 4. Eds.: Eckstein and Lilley, Berlin-Heidelberg: Springer-Verlag; pp. 90-109), and the FLP/FRT system from the *Saccharomyces cerevisiae* 2  $\mu$  circle plasmid (Broach *et al.* *Cell* 29:227-234 (1982)).

Members of the resolvase (Res) family of site-specific recombinases (*e.g.*,  $\gamma\delta$ , Tn3 resolvase, Hin, Gin, and Cin) are also known, and may be used in accordance with the present invention. Members of this highly related family of recombinases are typically constrained to intramolecular reactions (*e.g.*, inversions and excisions) and can require host-encoded factors. Mutants have been isolated that relieve some of the requirements for host factors (Maeser and Kahnmann (1991) *Mol. Gen. Genet.* 230:170-176), as well as some of the constraints of intramolecular recombination.

Other site-specific recombinases similar to  $\lambda$  Int and similar to P1 Cre can be substituted for Int and Cre. Such recombinases are known. In many cases the purification of such other recombinases has been described in the art. In cases when they are not known, cell extracts can be used or the enzymes can be partially purified using procedures described for Cre and Int.

5 While Cre and Int are described in detail for reasons of example, many  
related recombination systems and proteins exist and their application to the  
described invention is also provided according to the present invention. The  
10 integrase family of site-specific recombinases can be used to provide alternative  
5 recombination proteins and recombination sites for the present invention, as site-  
specific recombination proteins encoded by, for example bacteriophage lambda,  
15 phi 80, P22, P2, 186, P4 and P1. This group of recombination proteins, which  
may be used in the present compositions and methods, exhibits an unexpectedly  
large diversity of sequences. Despite this diversity, all of these recombinases can  
20 be aligned in their C-terminal halves. A 40-residue region near the C  
terminus is particularly well conserved in all the proteins and is homologous to  
a region near the C terminus of the yeast 2 mu plasmid FLP recombination  
protein. Three positions are perfectly conserved within this family: histidine,  
25 arginine and tyrosine are found at respective alignment positions 396, 399 and  
15 433 within the well-conserved C-terminal region. These residues contribute to the  
active site of this family of recombinases, and suggest that tyrosine-433 forms a  
transient covalent linkage to DNA during strand cleavage and rejoining. *See, e.g.,*  
30 *Argos, P. et al., EMBO J. 5:433-40 (1986).*

The recombinases of some transposons, such as those of conjugative  
20 transposons (e.g., Tn916) (Scott and Churchward. 1995. *Ann Rev Microbiol*  
35 49:367; Taylor and Churchward, 1997. *J Bacteriol* 179:1837), may also be used  
in the compositions and methods of the invention. These transposon  
recombinases belong to the integrase family of recombinases and in some cases  
40 show strong preferences for specific integration sites (Ike et al 1992. *J Bacteriol*  
25 174:1801; Trieu-Cuot et al, 1993. *Mol. Microbiol* 8:179).

Alternatively, IS231 and other *Bacillus thuringiensis* transposable  
45 elements could be used in accordance with the present invention as recombination  
proteins and recombination sites. *Bacillus thuringiensis* is an entomopathogenic  
bacterium whose toxicity is due to the presence in the sporangia of delta-  
30 endotoxin crystals active against agricultural pests and vectors of human and  
50 animal diseases. Most of the genes coding for these toxin proteins are plasmid-

borne and are generally structurally associated with insertion sequences (IS231, IS232, IS240, ISBT1 and ISBT2) and transposons (Tn4430 and Tn5401). Several of these mobile elements have been shown to be active and participate in the crystal gene mobility, thereby contributing to the variation of bacterial toxicity.

Structural analysis of the iso-IS231 elements indicates that they are related to IS1151 from *Clostridium perfringens* and distantly related to IS4 and IS186 from *Escherichia coli*. Like the other IS4 family members, they contain a conserved transposase-integrase motif found in other IS families and retroviruses. Moreover, functional data gathered from IS231A in *Escherichia coli* indicate a non-replicative mode of transposition, with a preference for specific targets. Similar results were also obtained in *Bacillus subtilis* and *B. thuringiensis*. See, e.g., Mahillon, J. *et al.*, *Genetica* 93:13-26 (1994); Campbell, J. *Bacteriol.* 7495-7499 (1992).

An unrelated family of recombinases, the transposases, have also been used to transfer genetic information between replicons, and may therefore be used as recombination proteins in accordance with the invention. Transposons are structurally variable, being described as simple or compound, but typically encode the recombinase gene flanked by DNA sequences organized in inverted orientations. Integration of transposons can be random or highly specific. Representatives such as Tn7, which are highly site-specific, have been applied to the efficient movement of DNA segments between replicons (Lucklow *et al.* 1993. *J. Virol* 67:4566-4579).

A related element, the integron, are also translocatable-promoting movement of drug resistance cassettes from one replicon to another. Often these elements are defective transposon derivatives. Transposon Tn21 contains a class I integron called In2. The integrase (Int1) from In2 is common to all integrons in this class and mediates recombination between two 59-bp elements or between a 59-bp element and an attI site that can lead to insertion into a recipient integron. The integrase also catalyzes excisive recombination. (Hall, 1997. *Ciba Found Symp* 207:192; Francia *et al.*, 1997. *J Bacteriol* 179:4419).

5 Group II introns are mobile genetic elements encoding a catalytic RNA  
and protein. The protein component possesses reverse transcriptase, maturase and  
10 an endonuclease activity, while the RNA possesses endonuclease activity and  
determines the sequence of the target site into which the intron integrates. By  
5 modifying portions of the RNA sequence, the integration sites into which the  
element integrates can be defined. Foreign DNA sequences can be incorporated  
15 between the ends of the intron, allowing targeting to specific sites. This process,  
termed retrohoming, occurs via a DNA:RNA intermediate, which is copied into  
cDNA and ultimately into double stranded DNA (Matsuura et al., Genes and Dev  
10 1997; Guo et al, EMBO J, 1997). Numerous intron-encoded homing  
endonucleases have been identified (Belfort and Roberts, 1997. NAR 25:3379).  
20 Such systems can be easily adopted for application to the subcloning methods  
described herein.

25 In addition, other suitable recombination proteins are described in detail  
15 in U.S. Application Nos. U.S. Application Nos. 08/486,139, filed June 7, 1995  
(now abandoned), 08/663,002, filed June 7, 1996 (now U.S. Patent No.  
5,888,732), 09/005,476, filed January 12, 1998, 60/065,930, filed October 24,  
30 1997, 09/177,387, filed October 23, 1998, 60/122,389, filed March 2, 1999,  
60/122,392, filed March 22, 1999, 60/126,049, filed March 23, 1999, and  
20 60/136,744, filed May 28, 1999, the disclosures of all of which are incorporated  
35 herein by reference in their entireties for their relevant teachings. Hence, in  
preferred compositions of the invention, the recombination protein may be  
selected from the group consisting of Int, Cre, Res, Xis, FLP, IHF and HU, and  
40 may be a site-specific recombination protein. Particularly preferred for use in the  
25 present compositions is Int.

45 The amount of recombination protein which is optimal for use in the  
compositions and methods of the present invention to drive the recombination  
reaction can be determined using known assays. Specifically, a titration assay  
may be used to determine the appropriate amount of a purified recombination  
30 protein, or the appropriate amount of an extract. Such assays are described in  
50 detail in the Examples below. In certain preferred compositions of the invention,

5 for example, the compositions may comprise an effective amount of  $\lambda$  Int, for  
example at a concentration range of about 1 ng to about 500 ng, about 2 ng to  
10 about 250 ng, about 5 ng to about 200 ng, about 10 ng to about 200 ng, about 25  
ng to about 200 ng, about 50 ng to about 200 ng, or about 100 ng to about 200 ng.  
5 In addition, the compositions may comprise one or more additional  
recombination proteins; for example, a composition of the invention may  
15 comprise  $\lambda$  Int at the above-indicated concentration ranges, and HU protein  
and/or IHF protein at concentration ranges of about 1 ng to about 50 ng, about 2  
ng to about 25 ng, about 5 ng to about 20 ng, about 5 ng to about 15 ng, or about  
10 5 ng to about 10 ng. Of course, other concentration ranges for  $\lambda$  Int or other  
20 recombination proteins that may be used in the present compositions may be  
determined by one of ordinary skill, without undue experimentation, by carrying  
out a titration assay as noted above and as described in detail in the Examples  
25 below.

#### 15 Recombinational Cloning Methods

30 The above-described compositions of the invention are suitable for use in  
recombination cloning methods that are provided by the present invention.  
Recombinational cloning using nucleic acid molecules comprising engineered  
20 recombination sites, and the materials and methods by which this technique may  
be accomplished, have been described in detail in U.S. Application Nos.  
35 08/486,139, filed June 7, 1995 (now abandoned), 08/663,002, filed June 7, 1996  
(now U.S. Patent No. 5,888,732), 09/005,476, filed January 12, 1998,  
40 60/065,930, filed October 24, 1997, 09/177,387, filed October 23, 1998,  
25 60/122,389, filed March 2, 1999, 60/122,392, filed March 22, 1999, 60/126,049,  
filed March 23, 1999, and 60/136,744, filed May 28, 1999. The disclosures of all  
45 of the above-referenced patent applications are incorporated herein by reference  
in their entireties for their relevant teachings.

In one such aspect, the invention relates to such methods comprising:

- 30 (a) combining *in vitro* or *in vivo*

- 5 (i) one or more Insert Donor molecules comprising one or  
more desired nucleic acid segments flanked by at least two  
10 recombination sites, wherein the recombination sites do  
not substantially recombine with each other;
- 5 (ii) one or more Vector Donor molecules comprising at least  
two recombination sites, wherein the recombination sites  
15 do not substantially recombine with each other;
- (iii) at least one recombination protein; and
- (iv) at least one ribosomal protein;
- 10 (b) incubating the combination formed in step (a) under conditions  
20 sufficient to transfer one or more of the desired segments into one  
or more of the Vector Donor molecules, thereby producing one or  
more desired Product nucleic acid molecules;

25 and optionally:

- 15 (c) combining *in vitro* or *in vivo*
- (i) one or more of the Product molecules comprising the  
30 desired segments flanked by two or more recombination  
sites, wherein the recombination sites do not substantially  
recombine with each other;
- 20 (ii) one or more different Vector Donor molecules comprising  
35 two or more recombination sites, wherein the  
recombination sites do not substantially recombine with  
each other;
- (iii) at least one recombination protein; and
- 40 (iv) at least one ribosomal protein; and
- 25 (d) incubating the combination formed in step (c) under conditions  
45 sufficient to transfer one or more of the desired segments into one  
or more different Vector Donor molecules, thereby producing one  
or more different Product molecules.

30 The invention also relates to such methods which further comprise  
50 incubating the different Product molecules with one or more different Vector



Donor molecules under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules.

In a related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

- a) combining *in vitro* or *in vivo*
  - i) one or more Insert Donor molecules comprising one or more nucleic acid segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
  - ii) two or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
  - iii) at least one recombination protein; and
  - iv) at least one ribosomal protein; and
- b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules, thereby producing two or more different Product molecules.

In another related aspect, the invention relates to methods for recombinational cloning of one or more desired nucleic acid molecules comprising

- (a) mixing one or more desired nucleic acid molecules with one or more vectors and with one or more of the compositions of the invention; and
- (b) incubating the mixture under conditions sufficient to transfer the one or more desired nucleic acid molecules into one or more of the vectors.

In another related aspect, the invention relates to methods for enhancement of recombinational cloning of nucleic acid molecules, comprising contacting one or more nucleic acid molecules with one or more ribosomal proteins and one or more recombination proteins, or with one or more

5 compositions of the invention, under conditions favoring the recombinational cloning of the one or more nucleic acid molecules.

10 According to the invention, the one or more ribosomal proteins used in these methods may be one or more prokaryotic or eukaryotic ribosomal proteins, such as those described herein. Similarly, the one or more recombination proteins may be one or more prokaryotic or eukaryotic recombination proteins such as those described herein.

15 In another related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

20 (a) combining *in vitro* or *in vivo*

(i) one or more Insert Donor molecules comprising one or more desired nucleic acid segments flanked by at least two recombination sites, wherein the recombination sites do not substantially recombine with each other;

25 (ii) one or more Vector Donor molecules comprising at least two recombination sites, wherein the recombination sites do not substantially recombine with each other; and

30 (iii) one or more of the compositions of the invention;

35 (b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into one or more of the Vector Donor molecules, thereby producing one or more desired Product nucleic acid molecules;

40 and optionally:

25 (c) combining *in vitro* or *in vivo*

45 (i) one or more of the Product molecules comprising the desired segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;

50 (ii) one or more different Vector Donor molecules comprising two or more recombination sites, wherein the

recombination sites do not substantially recombine with each other; and

- (iii) one or more of the compositions of the invention; and
- (d) incubating the combination formed in step (c) under conditions sufficient to transfer one or more of the desired segments into one or more different Vector Donor molecules, thereby producing one or more different Product molecules.

In another related aspect, the invention relates to methods of cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning comprising:

- a) combining *in vitro* or *in vivo*
  - i) one or more Insert Donor molecules comprising one or more nucleic acid segments flanked by two or more recombination sites, wherein the recombination sites do not substantially recombine with each other;
  - ii) two or more different Vector Donor molecules comprising two or more recombination sites, wherein the recombination sites do not substantially recombine with each other; and
  - iii) one or more of the compositions of the invention; and
- b) incubating the combination formed in step (a) under conditions sufficient to transfer one or more of the desired segments into the different Vector Donor molecules, thereby producing two or more different Product molecules.

According to the invention, the Insert Donor molecules for use in the compositions and methods of the invention may be derived from genomic DNA or cDNA, or may be produced by chemical synthesis methods. In a related aspect, the Insert Donor molecules may comprise one or more vectors.

The Vector Donor molecules for use in the compositions and methods of the invention may optionally comprise at least one Selectable marker, which allows for the selection of host cells comprising the Product molecules

5 comprising the Selectable markers contributed by the Vector Donor molecules during the recombination reaction. According to this aspect of the invention, the  
10 Selectable Marker may be an antibiotic resistance gene, a tRNA gene, an auxotrophic marker, a toxic gene, a phenotypic marker, an antisense oligonucleotide, a restriction endonuclease, a restriction endonuclease cleavage  
15 site, an enzyme cleavage site, a protein binding site, and a sequence complementary to a PCR primer sequence. In a related aspect, the Vector Donor molecules may comprise one or more eukaryotic vectors or one or more prokaryotic vectors. Eukaryotic vectors suitable for use in this aspect of the  
20 invention may comprise, for example, vectors which propagate and/or replicate in yeast cells, plant cells, fish cells, eukaryotic cells, mammalian cells, and/or insect cells, while suitable prokaryotic vectors may comprise, for example, vectors which propagate and/or replicate in bacteria of the genera *Escherichia* (most particularly *E. coli*), *Salmonella*, *Bacillus*, *Streptomyces* or *Pseudomonas*.

15 The compositions and methods described herein are suitable for use in recombination cloning according to the present invention. However, wild-type recombination sites that are contained in the Insert Donor and/or Vector Donor DNA molecules may contain sequences that reduce the efficiency or specificity of recombination reactions or the function of the Product molecules as applied in  
30 methods of the present invention. For example, multiple stop codons in attB, attR, attP, attL and loxP recombination sites occur in multiple reading frames on both strands, so translation efficiencies are reduced, *e.g.*, where the coding sequence must cross the recombination sites, (only one reading frame is available on each strand of loxP and attB sites) or impossible (in attP, attR or attL).

25 Accordingly, DNA molecules comprising one or more engineered recombination sites are preferably used in the methods of the present invention, to overcome these problems. For example, att sites can be engineered to have one  
45 or multiple mutations to enhance specificity or efficiency of the recombination reaction and the properties of Product DNAs (*e.g.*, att1, att2, and att3 sites); to decrease reverse reaction (*e.g.*, removing P1 and H1 from attR). The testing of  
30 these mutants determines which mutants yield sufficient recombinational activity

5 to be suitable for recombination subcloning according to the present invention.  
Hence, in addition to the one or more ribosomal proteins and one or more  
10 recombination proteins described herein, the compositions of the invention may  
further comprise one or more nucleic acid molecules including, but not limited  
5 to, one or more Insert Donor molecules, one or more Vector Donor molecules,  
one or more cointegrate molecules, one or more Product molecules and one or  
15 more Byproduct molecules, any or all of which may contain engineered or mutant  
recombination sites.

Mutations can be introduced into recombination sites for enhancing site  
10 specific recombination. The production of DNA molecules comprising one or  
more mutated engineered recombination sites, which molecules may be used as  
Insert Donor or Vector Donor molecules in the recombinational cloning methods  
of the present invention, is described in detail in U.S. Application Nos.  
20 08/486,139, filed June 7, 1995 (now abandoned), 08/663,002, filed June 7, 1996  
(now U.S. Patent No. 5,888,732), 09/005,476, filed January 12, 1998,  
15 60/065,930, filed October 24, 1997, 09/177,387, filed October 23, 1998,  
60/122,389, filed March 2, 1999, 60/122,392, filed March 22, 1999, 60/126,049,  
30 filed March 23, 1999, and 60/136,744, filed May 28, 1999, the disclosures of all  
of which applications are incorporated herein by reference in their entireties.  
20 Particularly preferred for use in the compositions and methods of the present  
invention are nucleic acid molecules comprising at least one DNA segment  
35 having at least two engineered recombination sites flanking a Selectable marker  
and/or a desired DNA segment, wherein at least one of the recombination sites  
comprises a core region having at least one engineered mutation that enhances  
40 recombination *in vitro* in the formation of a Cointegrate DNA or a Product DNA.  
25

In accordance with the invention, any vector may be used to construct the  
Vector Donors used in the methods of the invention. In particular, vectors known  
45 in the art and those commercially available (and variants or derivatives thereof)  
may in accordance with the invention be engineered to include one or more  
30 recombination sites for use in the methods of the invention. Such vectors may be  
obtained from, for example, Vector Laboratories Inc., InVitrogen, Promega,  
50

5 Novagen, NEB, Clontech, Boehringer Mannheim, Pharmacia, EpiCenter,  
OriGenes Technologies Inc., Stratagene, Perkin Elmer, Pharmingen, Life  
10 Technologies, Inc., and Research Genetics. Such vectors may then for example  
5 be used for cloning or subcloning nucleic acid molecules of interest. General  
classes of vectors of particular interest include prokaryotic and/or eukaryotic  
15 cloning vectors, expression vectors, fusion vectors, two-hybrid or reverse two-  
hybrid vectors, shuttle vectors for use in different hosts, mutagenesis vectors,  
transcription vectors, vectors for receiving large inserts and the like. Particularly  
20 preferred vectors (and mutants, derivatives, or variants thereof) that may be used  
to construct the Vector Donors used in the methods of the invention are described  
in detail in U.S. Application Nos. 08/486,139, filed June 7, 1995 (now  
abandoned), 08/663,002, filed June 7, 1996 (now U.S. Patent No. 5,888,732),  
09/005,476, filed January 12, 1998, 60/065,930, filed October 24, 1997,  
25 09/177,387, filed October 23, 1998, 60/122,389, filed March 2, 1999, 60/122,392,  
15 filed March 22, 1999, 60/126,049, filed March 23, 1999, and 60/136,744, filed  
May 28, 1999, the disclosures of all of which applications are incorporated herein  
30 by reference in their entireties.

#### **DNA Molecules, Vectors and Host Cells**

20 The invention also relates generally to DNA molecules produced by the  
35 methods of the invention, particularly to such DNA molecules which are isolated  
DNA molecules. Methods for the isolation of DNA molecules produced by the  
methods of the invention will be familiar to one of ordinary skill in the art, and  
40 are described generally in U.S. Application Nos. 08/486,139, filed June 7, 1995  
(now abandoned), 08/663,002, filed June 7, 1996 (now U.S. Patent No.  
25 5,888,732), 09/005,476, filed January 12, 1998, 60/065,930, filed October 24,  
1997, 09/177,387, filed October 23, 1998, 60/122,389, filed March 2, 1999,  
45 60/122,392, filed March 22, 1999, 60/126,049, filed March 23, 1999, and  
60/136,744, filed May 28, 1999, the disclosures of which are incorporated herein  
30 by reference in their entireties. In addition, the isolated DNA molecules of the  
50 invention may be inserted into standard nucleotide vectors suitable for

transfection or transformation of a variety of prokaryotic (bacterial) or eukaryotic (yeast, plant or animal including human and other mammalian) host cells. Vectors suitable for these purposes, and methods for insertion of DNA fragments therein, will be well-known to one of ordinary skill in the art. Thus, the present invention also relates to vectors comprising such DNA molecules, and to host cells comprising such DNA molecules and/or vectors.

#### Kits

The invention also relates to kits for use in recombinational cloning of a nucleic acid molecule. Kits according to the present invention may comprise a carrying means being compartmentalized to receive in close confinement therein one or more containers such as vials, tubes, bottles, ampules and the like. Each of such containers may comprise components or a mixture of components needed to perform recombinational cloning of nucleic acid molecules, particularly according to the methods of the present invention.

In one such aspect, the kits of the invention may comprise at least one ribosomal protein and at least one recombination protein. Ribosomal proteins and recombination proteins suitable for use in the kits of the invention include, but are not necessarily limited to, those prokaryotic and eukaryotic ribosomal and recombination proteins described in detail herein. Of course, it is also possible to combine one or more of these components into a single container, such that the kit will contain one or more containers wherein a first container contains at least one ribosomal protein and at least one recombination protein, or wherein a first container contains one or more of the above-described compositions of the invention. Additional kits of the invention may comprise one or more additional containers containing additional components which may be useful in carrying out recombinational cloning of nucleic acid molecules, including, for example, one or more polymerases (such as one or more thermostable DNA polymerases like *Taq*, *Tne*, *Tma*, and the like), one or more polypeptides having reverse transcriptase activity (such as RSV or ASLV reverse transcriptases, particularly

those that are substantially reduced in RNase H activity), one or more restriction endonucleases, one or more buffers, one or more detergents, and the like.

### *Applications*

There are a number of applications for the compositions, methods and kits of the present invention. These uses include, but are not limited to, changing vectors, operably linking genes to regulatory genetic sequences (*e.g.*, promoters, enhancers, and the like), constructing genes for fusion proteins, changing copy number, changing replicons, cloning into phages, and cloning, *e.g.*, PCR products (with an *attB* site at one end and a *loxP* site at the other end), genomic DNAs, and cDNAs. Such applications are described in detail, for example, in U.S. Application Nos. 08/486,139, filed June 7, 1995 (now abandoned), 08/663,002, filed June 7, 1996 (now U.S. Patent No. 5,888,732), 09/005,476, filed January 12, 1998, 60/065,930, filed October 24, 1997, 09/177,387, filed October 23, 1998, 60/122,389, filed March 2, 1999, 60/122,392, filed March 22, 1999, 60/126,049, filed March 23, 1999, and 60/136,744, filed May 28, 1999, the disclosures of all of which applications are incorporated herein by reference in their entireties.

It will be understood by one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are readily apparent and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.

### *Examples*

The present recombinational cloning methods accomplish the exchange of nucleic acid segments to render something useful to the user, such as a change



of cloning vectors. These segments must be flanked on both sides by recombination signals that are in the proper orientation with respect to one another. In the examples below the two parental nucleic acid molecules (e.g., plasmids) are called the Insert Donor and the Vector Donor. The Insert Donor contains a segment that will become joined to a new vector contributed by the Vector Donor. The recombination intermediate(s) that contain(s) both starting molecules is called the Cointegrate(s). The second recombination event produces two daughter molecules, called the Product (the desired new clone) and the Byproduct.

### **Buffers**

Various known buffers can be used in the reactions of the present invention. For restriction enzymes, it is advisable to use the buffers recommended by the manufacturer. Alternative buffers can be readily found in the literature or can be devised by those of ordinary skill in the art. One exemplary buffer for lambda integrase is comprised of 50 mM Tris-HCl, at pH 7.5-7.8, 70 mM KCl, 5 mM spermidine, 0.5 mM EDTA, and 0.25 mg/ml bovine serum albumin, and optionally, 10% glycerol. Suitable buffers for other site-specific recombinases which are similar to lambda Int are either known in the art or can be determined empirically by the ordinarily skilled artisan, particularly in light of the above-described buffers.

### **Example 1: Stimulation of Integrase by *E. coli* Ribosomal Proteins**

## **MATERIALS AND METHODS**

**DNAs for Recombination Assays.** Plasmid pHN894 (Figure 2), bearing an *attP* site, and plasmid pBB105 (Figure 3), bearing an *attB* site, are described (Kitts, P.A. and Nash, H.A. *J. Mol. Biol.* 204: 95-107 (1988); Nash, H.A. *Methods Enz.* 100: 210-216 (1983)). pBB105 was cut with *EcoRI* before use. Plasmid pHN872 (Figure 4), bearing an *attL* site, and plasmid pHN868 (Figure

5), bearing an *attR* site, are described (Kitts, P.A. and Nash, H.A. *J. Mol. Biol.* 204: 95-107 (1988)). pHN872 was cut with *SaII* before use. These plasmids were propagated in *E. coli* strain DH10B. To grow cells for preparation of plasmid DNA, the growth medium contained in one liter: 12 g of tryptone, 24 g of yeast extract, 2.3 g of  $\text{KH}_2\text{PO}_4$ , 12.5 g of  $\text{K}_2\text{HPO}_4$ , 0.01% (v/v) PPG antifoam, and appropriate antibiotic. Cells from a glycerol seed were placed in 25 ml of medium containing 100 µg/ml ampicillin (pBB105, pHN894, pHN868) or 100 µg/ml kanamycin (pHN872) and grown overnight at 37°C. Fifteen ml of overnight culture was added to 1.5 L medium containing 10 µg/ml appropriate antibiotic and cells were grown to a  $A_{600}$  of ~2.0. Chloramphenicol was then added to a final concentration of 170 µg/ml and growth was continued for 16 hr at 37 °C. Cells were harvested by centrifugation and stored at -70°C. Plasmid DNAs were purified as follows. Frozen cells were thawed on ice and suspended in 7 ml/g cells of 25 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 50 mM glucose (TEG) + 100 µg/ml of RNaseA + 1 mg/ml lysozyme. A solution of 1% (w/v) SDS- 0.125 N NaOH at 14 ml/g cells was then added to lyse cells. After 10 minutes on ice, 7.5 M ammonium acetate at 10.5 ml/g cells was added. After 10 minutes on ice, the mixture was centrifuged at 28,000 x g for 10 minutes and the supernatant was collected. DNA was precipitated by addition of 0.6 volumes of cold isopropanol, and DNA was pelleted by centrifugation at 28,000 x g for 10 minutes. The DNA pellet was dissolved in 10 mM Tris-HCl (pH 7.5) - 1 mM EDTA ( $T_{10}E_1$ ) + RNase A (100 µg/ml) + RNaseT1 (1,200 U/ml). After phenol extraction and ethanol precipitation of the DNA, it was dissolved in  $T_{10}E_1$ . The DNA was dialyzed against 100 volumes of 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 450 mM NaCl ( $T_{10}E_1N_{450}$ ) overnight. The dialyzed DNA was applied to a NACS-37 column (LTI) equilibrated in  $T_{10}E_1N_{450}$ . The column was washed with 10 column volumes of  $T_{10}E_1N_{450}$  and eluted with a 15-column volume linear gradient from 0.45 M to 0.65 M NaCl in  $T_{10}E_1$ . Fractions were analyzed by agarose gel electrophoresis and those containing supercoiled DNA were pooled. The pooled DNA was dialyzed against  $T_{10}E_1$  and stored at -20°C.

Plasmid pEZ13835 (Figure 6; *attP*), pEZC7501 (Figure 7; *attB*), pEZ11104 (Figure 8; *attR*), and pEZC8402 (Figure 9; *attL*) were as shown. pEZC7501 was cut with *ScaI* and pEZC8402 with *NcoI* before use. pEZ13835 and pEZC8402 were propagated in *E. coli* DB2 and the other two in *E. coli* DH5 $\alpha$ . Cells from a glycerol seed were placed in 25 ml of Circlegrow (BIO 101) plus 100  $\mu$ g/ml ampicillin (pEZC7501 and pEZC8402) or plus 100  $\mu$ g/ml kanamycin (pEZ13835 and pEZ11104) and grown overnight at 37 °C. Cells were harvested by centrifugation and stored at -70 °C. Plasmid DNAs were purified using Qiagen Midi products and protocols.

**SDS PAGE.** Tris-Tricine SDS PAGE 16% precast mini gels (Novex) were used to analyze protein samples. The samples were prepared by mixing with an equal volume of 0.9 M Tris-HCl (pH 8.45), 24% (v/v) glycerol, 8% (w/v) SDS, 0.015% (w/v) Coomassie BlueG, 0.005% (w/v) Phenol Red, and 0.05 M dithiothreitol and boiling for 3 to 5 min. Gels were run at 125 volts in 0.1 M Tris-Tricine (pH 8.3)-0.1% (w/v) SDS for 90 min. Gels were stained in 50% (v/v) methanol, 10% (v/v) acetic acid, and 1 mg/ml Coomassie Blue R-250 solution followed by destaining in 20% (v/v) methanol, 10% (v/v) acetic acid solution.

**Determination of Protein Concentration.** S20, Int, and Xis bind Bradford reagent dye poorly, so that the Bradford procedure was not used to determine protein concentration. Rather, for Int and Xis, protein concentration was estimated by comparison to Coomassie Blue-stained band intensities of a known amount of BenchMark protein standard of a similar size run along with Int or Xis on an SDS gel. For S20, protein concentration was established using an extinction coefficient at 278 nm of  $0.140 \times 10^4 \text{ M}^{-1}\text{cm}^{-1}$  (*Eur. J. Biochem.* 126: 299-309 (1982)).

**PCR.** PCR reaction mixtures (50  $\mu$ l) contained 22 mM Tris-HCl (pH 8.4), 55 mM KCl, 1.65 mM MgCl<sub>2</sub>, 200  $\mu$ M each of dATP, dCTP, dTTP, and dGTP, 1  $\mu$ M of each primer, 300 ng of DNA template, and 1.1 units of Taq DNA polymerase. Initial template denaturation was at 95 °C for 5 minutes.

*Purification of IHF.* The strain used for overproduction of IHF is described (Nash, H.A. *et. al. J. Bacteriol.* 169: 4121-4127 (1987)). IHF was purified as described (Rice, P.A. *et. al. Cell* 87: 1295-1306 (1996)).

*Purification of Native Int.* Native Int was purified from *E. coli* strain HN695 (Lange-Gustafson, B.J. and Nash, H.A. *J. Biol. Chem.* 259:12724-12732 (1984)) by a modification of published procedures (Nash, H.A. *Methods Enz.* 100:210-216 (1983)).

*Growth of Cells.* Cells from a glycerol stock of strain HN695 were inoculated into 50 ml of LB broth containing 25 µg/ml ampicillin in a 250-ml flask. The culture was grown at 31 °C in an air shaker to an  $A_{650}$  of 0.6 to 1.4. This seed culture was used to inoculate six 2.8-L flasks containing 500 ml of growth medium each and cells were grown as just stated. These cultures were used to inoculate 360 L of growth medium in a 500-L fermentor. Cells were grown at 31°C with aeration (190 rpm) and agitation (200 rpm) to an  $A_{650}$  of 0.65, and were harvested in a chilled centrifuge. Cell paste (~ 400 g) was brought to 600 ml by addition of ice-cold 50 mM Tris-HCl (pH 7.5) containing 10% (w/v) sucrose and homogenized in a Waring blender at low speed. The slurry was divided into 40-ml aliquots, frozen in dry ice, and stored at -70 °C.

*Preparation of Extract.* Three tubes of frozen cells (60 g) were thawed at room temperature and placed on ice. To each tube, 2 ml of a 10 mg/ml solution of lysozyme in 250 mM Tris-HCl (pH 7.5) was added, and the tubes were mixed thoroughly. After 35 min on ice, the mixture was centrifuged at 32,600 x g for 45 min. The supernatant was retained (57 ml).

*Differential Salt Precipitation.* The supernatant was diluted with 50 mM Tris-HCl (pH 7.5) to 100 ml and centrifuged at 4 °C and 41,000 rpm (170,000 x g) for 200 min in a precooled Sorval T865 rotor. The supernatant was decanted, frozen, and stored at -70 °C. The pellet was stored at -70°C. Thawed pellet was resuspended with the aid of a Teflon pestle in Buffer X (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM β-mercaptoethanol, and 10% (w/v) glycerol) + 0.6 M KCl. After adjusting to a volume of 50 ml with the same buffer, the mixture was stirred at 4°C for 1 hr and centrifuged in a Sorval T865 rotor as before. The clear,

5 straw-colored supernatant was carefully removed, frozen in dry ice, and stored at  
-70°C.

10 *Phosphocellulose Chromatography.* After thawing, the second supernatant  
was loaded at 38 cm/hr on a 4.5- ml phosphocellulose column (Whatman P-11)  
5 equilibrated in Buffer X + 0.6 M KCl and the column was washed with 5 column  
volumes of Buffer X + 0.6 M KCl. The column was developed with a 10-column  
15 volume linear gradient of Buffer X + 0.6 M KCl to Buffer X + 1.7 M KCl at 19  
cm/hr. Int-containing fractions eluting between 0.7 and 1.1 M KCl were pooled  
and stored at -70 °C.

20 *Hydroxyapatite Chromatography.* The phosphocellulose pool was loaded  
at 38 cm/hr on a 1.5-ml hydroxyapatite column (Bio-Rad, ceramic, type II)  
equilibrated in Buffer X + 0.6 M KCl. The pool was diluted with Buffer X to  
25 match the ionic strength of Buffer X + 0.6 M KCl before loading. The column  
was washed with buffer X + 1 M KCl. Int was eluted at 19 cm/hr with a 10-  
15 column volume linear gradient of Buffer X + 0.6 M KCl to Buffer X + 0.6 M  
KCl + 0.025 M KPO<sub>4</sub>. Int-containing fractions were pooled, BSA was added to  
30 2 mg/ml, and the pool was frozen at -70 °C.

#### 20 *Purification of Stimulatory Protein as a Side Fraction of a Native Int Preparation*

35 Cells were grown and harvested and cell extract was prepared as described  
in the Materials and Methods section Purification of Native Int. The clarified cell  
extract (~ 60 ml) was diluted to 100 ml with Buffer X (see section: Purification  
40 of Native Int) and centrifuged at 4 °C at 41,000 rpm in a Sorval T865 rotor for  
25 200 min. The supernatant was divided into 25 ml aliquots in 50 ml conical tubes  
and submerged into a boiling water bath for 30 minutes. The heated suspension  
45 was centrifuged at 27,000 x g for 45 minutes. The supernatant was collected and  
diluted with Buffer X + 1.7 M KCl to match the ionic strength of Buffer X +  
30 0.6 M KCl and loaded at 15 cm/hr onto a 18 ml phosphocellulose (Whatman P-  
11) column (1.6 x 9 cm) which had been equilibrated in Buffer X + 0.6 M KCl.  
50 The column was washed with 10 column volumes of Buffer X + 0.6 M KCl and

developed with a 10-column volume linear gradient of Buffer X + 0.6 M KCl to Buffer X + 1.7 M KCl. Fractions were stored at -70° C. SDS PAGE analysis of aliquots of the fractions revealed a single protein band migrating with an apparent molecular weight of 11 kDa. The protein eluted at 1.2 M KCl. Fractions containing the 11-KDa protein were pooled and diluted with Buffer X to match the ionic strength of Buffer X + 0.2 M KCl. The diluted pool was loaded at 76 cm/hr onto a 1 ml Mono S column (Pharmacia) equilibrated in Buffer X + 0.2 M KCl. The protein was eluted with Buffer X + 1.0 M KCl. Fractions containing the peak of 11-KDa protein were pooled and stored at -70° C. The protein was subjected to amino-terminal amino acid sequence analysis as described in Materials and Methods section Amino-Terminal Amino Acid Sequence Analysis of Stimulatory Proteins and found to be ribosomal protein S20.

***Purification of Stimulatory Proteins from Cells Producing Native Int***

Cells were grown and harvested as described in Materials and Methods section Purification of Native Int. Cell slurry (60 g cells) was thawed at room temperature and placed on ice. A 20 mg/ml solution of lysozyme in 250 mM Tris-HCl (pH 7.4) was added in a volume 1/20 the volume of cells. After 40 minutes on ice with occasional mixing, KCl was added to a final concentration of 0.6 M. The slurry was divided into 25 ml aliquots in 50 ml conical tubes and submerged in a 72°C water bath for 25 minutes. The suspension was spun at 27,000 x g for 45 minutes. The supernatant was loaded at 15 cm/hr onto a 10 ml phosphocellulose column (Whatman P-11) (1.6 x 5 cm) equilibrated in Buffer X + 0.6 M KCl. The column was washed with 10 column volumes of Buffer X + 0.6 M KCl and developed with a 10-column volume linear gradient of Buffer X + 0.6 M KCl to 1.7 M KCl. The fractions were assayed for ability to stimulate  $\lambda$  integrase activity (see Materials and Methods section Integrative Recombination Gel Assay). Two peaks of stimulating activity were found. Two pools were made, from fractions eluting at ~ 0.8 M KCl (Pool 1) and from fractions eluting at ~ 1.2 M KCl (Pool 2), and stored at -70° C.

The pools were processed separately on Mono S. Each pool was diluted with Buffer X to match the ionic strength of Buffer X + 0.2 M KCl and loaded at 76 cm/hr onto a 1 ml Mono S column (Pharmacia) equilibrated with Buffer X + 0.2 M KCl. The column was washed with 10 column volumes of Buffer X + 0.2 M KCl and developed with a 20-column volume linear gradient of Buffer X + 0.2 M KCl to Buffer X + 1.7 M KCl. Fractions were stored at -70° C.

The fractions from each column were assayed for ability to stimulate  $\lambda$  integrase activity. Pool 1 from phosphocellulose was fractionated into two activity peaks by Mono S. The primary protein band in the first peak (Figure 18, lanes A and B) was determined by N-terminal amino acid sequence analysis to be ribosomal protein L27 (see Materials and Methods section Amino-Terminal Amino Acid Sequence Analysis of Stimulatory Proteins). The second peak eluting later in the gradient was found to be composed of two major protein bands by SDS PAGE analysis (Figure 18, lanes C and D). One protein co-migrated with L27 and the other migrated more slowly than L27 and S20 (lane E). Pool 2 from phosphocellulose was fractionated into one peak of activity by Mono S which eluted at a slightly higher salt concentration than the second peak of Pool 1 on Mono S. The main protein in this activity peak co-migrated during SDS-PAGE analysis with S20 protein (Figure 18, lanes F and G).

#### *Amino-Terminal Amino Acid Sequence Analysis of Stimulatory Proteins*

Protein samples were subjected to SDS PAGE as described in Materials and Methods section SDS PAGE. The gel was equilibrated in transfer buffer (0.05 M Tris, 0.04 M boric acid, 0.5 mM EDTA, 20% (v/v) methanol (pH 8.4)). PVDF membrane (Immobilon P from Millipore) was prepared according to manufacturer's instructions and equilibrated in transfer buffer. The protein was transferred to the membrane using a BioRad mini blotting apparatus at 100 volts for 1 hour. The membrane was stained with Coomassie Blue R-250 staining solution and destained in 100% (v/v) methanol. The membrane was air dried and

the stained protein band was excised from the membrane and stored in a 1.5-ml microcentrifuge tube.

Amino-terminal amino acid sequence analysis was performed on membrane bound protein samples by automated Edman sequence analysis by the HHMI Biopolymer Laboratory, W.M. Keck Foundation, New Haven, CT.

#### *Cloning of Int-His<sub>6</sub>*

The following two oligonucleotides were used to clone the Int gene: TAT TAT TAT CAT ATG GGA CGA CGT CGA AGT CAT GAG CGC CGG GAT (SEQ ID NO:1) and A TTA TTA AGC TTA TTA ATG GTG ATG ATG GTG ATG TTT GAT TTC AAT TTT GTC CCA CTC (SEQ ID NO:2). The oligonucleotides were used to generate a 1,092-bp PCR amplification product using  $\lambda$  DNA as the template. DNA was amplified (Materials and Methods section PCR) during 8 cycles composed of the following steps: 95 °C for 15 seconds, 55°C for 15 seconds, and 72 °C for 90 seconds. The 1,092-bp PCR product was digested with *Nde*I and *Hind*III and cloned into the *Nde*I and *Hind*III sites of plasmid pTRCN2 (Figure 10) in an *E. coli* DH10B host. This construct is called pTRCN2INT2 (Figure 11). The Int gene is under control of a pTRC promoter and contains a sequence coding for a His<sub>6</sub> tag at the carboxy end of the protein. The DNA sequence of the Int gene in pTRCN2INT2 was determined and found to match the published sequence, except as modified below. Arg codons AGA and AGG originally coding for Arg at positions 3 and 4 were changed to CGA and CGT, respectively, which are Arg codons more frequently used in *E. coli*.

#### *Purification of Int-His<sub>6</sub>*

Int-His<sub>6</sub> was purified from *E. coli* DH10B cells bearing plasmid pTRCN2INT2 (see Materials and Methods section Cloning of Int-His<sub>6</sub>).

*Growth of Cells.* To prepare seed stocks, *E. coli* DH10B cells bearing plasmid pTRCN2INT2 were grown at 30 °C in Buffered Rich medium +



100 µg/ml ampicillin to an  $A_{590}$  ~2. Culture was mixed 1:1 with 50% glycerol. The mixture was aliquoted by 1 ml into cryovials on ice and then stored at -80 °C.

For a small scale growth, cells from a frozen glycerol stock were inoculated into 2 x 50 ml Buffered Rich medium + 100 µg/ml ampicillin in 2 x 250-ml bottom-baffled shake flasks. Cells were grown for 16.5 hours at 30 °C and 250 rpm to an  $A_{590}$  of ~4.0. Twenty-five ml of the primary shake flask growth was used to inoculate each of 4, 2.8-L bottom-baffled Fernbach flasks containing 1 L of Buffered Rich medium + 100 µg/ml ampicillin (for an initial  $A_{590}$  of ~0.1). Cultures were grown at 30 °C until an  $A_{590}$  = 1.0 to 1.5 was achieved. The cultures were induced by adding IPTG to 1 mM. Growth was continued for 2 hr at 30 °C. The culture was chilled by icing in 4 x 1 L centrifuge bottles and harvested by centrifugation at 4,500 rpm (5,895 x g) and 4 °C for 12 minutes. Each pellet was washed by resuspension in ~7 ml 50 mM Tris-HCl (pH 8.0), 100 mM NaCl at 4 °C and re-spun. The pellets were frozen and stored at -80 °C.

For a large scale growth, 50 ml of Buffered Rich medium + 100 µg/ml ampicillin in a 250 ml bottom baffled shake flask was inoculated with 1 ml of a frozen seed. Cells were grown at 30 °C and 250 rpm to an  $A_{590}$  of 0.8 to 1.2. The entire 50 ml was inoculated into 500 ml Buffered Rich medium + 100 µg/ml in a 2.8-L bottom-baffled Fernbach. Growth was continued at 30 °C and 250 rpm to an  $A_{590}$  = 0.8 to 1.2.

10 L of Buffered Rich medium + 100 µg/ml ampicillin in a 14-L vessel was inoculated with all 500 ml of culture. Temperature was maintained at 30 °C. Dissolved oxygen levels were controlled at >30% and pH at 7 +/- 0.3. At  $A_{590}$  = 1.5 to 2.0 the culture was induced by adding IPTG to 1 mM. Growth was continued for 2 hr at 30 °C. The vessel was chilled and harvested by centrifugation in a Sharples centrifuge. Cell paste was frozen and stored at -80C.

*Purification.* Frozen cells (20 g) were thawed on ice and suspended in 40 ml of Tris-HCl (pH 8.0)-10% (w/v) sucrose. Cells were disrupted on ice by sonication (4, 30 second bursts at 70% maximum setting), and the extract was centrifuged at 27,000 x g for 30 minutes at 4 °C. The supernatant was collected. The supernatant was mixed with 20 ml (packed volume) of Chelating Sepharose

(Pharmacia) charged with  $\text{NiSO}_4$  and equilibrated with Buffer A (50 mM Tris-HCl (pH 8.0), 0.3 M NaCl, 10% (v/v) glycerol). The slurry was transferred to 50-ml conical tubes and was gently rocked for 30 minutes at 4 °C. The slurry was then packed into a 1.6 cm column and attached to an FPLC system (Pharmacia). The column was washed with 20 column volumes of Buffer A + 20 mM Imidazol at 30 cm/hr. The protein was eluted with a 15-column volume linear gradient from Buffer A + 20 mM Imidazol to Buffer A + 500 mM Imidazol. Fractions were analyzed by SDS PAGE. Fractions containing Int-His<sub>6</sub> were pooled and 0.5 M EDTA was added to a final concentration of 1 mM. The pool was then transferred to 10,000 molecular weight cut off (MWCO) dialysis tubing and dialyzed against 50 volumes of Buffer B (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10% (v/v) glycerol, and 1 mM  $\beta$ -mercaptoethanol). The dialyzed pool was loaded at 38 cm/hr onto a 2 ml (1 x 1 cm) EMD-SO<sub>4</sub> (EM Separations) column equilibrated in Buffer B + 0.2 M NaCl. The column was washed with 10 column volumes of Buffer B + 0.2 M NaCl at 76 cm/hr and developed with a 15-column volume linear gradient from Buffer B + 0.2 M NaCl to Buffer B + 1.6 M NaCl. Int-His<sub>6</sub> eluted at approximately 1.1 M NaCl based upon analysis by SDS PAGE. The peak fractions were pooled and the pool was transferred to 10,000 MWCO dialysis tubing and dialyzed against 100 volumes of Buffer C (Buffer B minus EDTA). The dialyzed pool was loaded at 38 cm/hr onto a 1 ml (0.5 x 1 cm) hydroxyapatite column (Type II, BioRad) equilibrated in Buffer C. The column was washed with 10 column volumes of Buffer C + 1 M NaCl and developed with 10 column volumes of Buffer C + 0.6 M NaCl + 25 mM KPO<sub>4</sub> at 19 cm/hr. The fractions were analyzed by SDS PAGE and the peak fractions containing Int-His<sub>6</sub> were pooled. The pool was transferred to 10,000 MWCO dialysis tubing and was dialyzed against 200 volumes of 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.05 mM EDTA, 50% (v/v) glycerol, and 1 mM DTT overnight at 4° C. The final sample was stored at -70° C.

### *Cloning of Xis-His<sub>6</sub>*

The following two oligonucleotides were used to clone the Xis gene: TAT TAT TAT CAT ATG TAC TTG ACA CTT CAG GAG (SEQ ID NO:3) and ATT ATT AAG CTT ATT AAT GGT GAT GAT GGT GAT GTG ACT TCG CCT TCT TCC CAT T (SEQ ID NO:4). The oligonucleotides were used to generate a 219-bp PCR product using  $\lambda$  DNA as the template. DNA was amplified (Materials and Methods section PCR) during 15 cycles composed of the following steps: 95 °C for 15 seconds, 55 °C for 15 seconds, and 72 °C for 60 seconds. The 219-bp PCR product was digested with *Nde*I and *Hind*III and cloned into the *Nde*I and *Hind*III site of pTRCN2 (Figure 10). The resulting construct was called pTRCN2XIS1 (Figure 12). The Xis gene is under control of a pTRC promoter and contains a sequence coding for a His<sub>6</sub> tag at the carboxy end of the protein. The DNA sequence of the Xis gene in pTRCN2XIS1 was determined and found to match the published sequence.

### *Purification of Xis-His<sub>6</sub>*

Xis-His<sub>6</sub> was purified from *E. coli* Stbl 2 cells bearing plasmid pTRCN2XIS1 (see Materials and Methods section Cloning of Xis-His<sub>6</sub>).

**Growth of Cells.** To prepare seed stocks, *E. coli* Stbl 2 cells bearing plasmid pTRCN2XIS1 were grown at 37 °C in Buffered Rich medium + 100 µg/ml ampicillin to an A<sub>590</sub> ~3. Culture was mixed 1:1 with 50% glycerol. The mixture was aliquoted by 1 ml into cryovials on ice and then stored at -70 °C.

For small scale growths, cells from a frozen glycerol stock were inoculated into 50 ml Buffered Rich medium + 100 µg/ml ampicillin in a 250-ml bottom-baffled shake flask. Cells were grown for 17 hours at 37 °C and 250 rpm to an A<sub>590</sub> of ~4.0.

12 ml of the primary shake flask growth was used to inoculate each of 4, 2.8-L bottom-baffled Fernbach flasks containing 1 L of Buffered Rich medium + 100 µg/ml ampicillin (for an initial A<sub>590</sub> of ~0.05). Cultures were grown at 37 °C until an A<sub>590</sub> = 1.5 to 2.0 was achieved. The cultures were induced by adding IPTG to 1 mM. Growth was continued for 2 hr at 37 °C. The culture was chilled

by icing in 4 x 1 L centrifuge bottles and harvested by centrifugation at 4,500 rpm (5,895xg) and 4 °C for 15 minutes. Each pellet was washed by resuspension in ~20 ml used medium and re-spun. The pellets were frozen and stored at -70 °C.

For a large scale growth, a 50 ml culture of Buffered Rich medium + 100 µg/ml ampicillin in a 250-ml bottom baffled shake flask was inoculated with 1 ml of a frozen seed. Cells were grown at 37 °C and 250 rpm to an  $A_{590}$  of 0.6 to 1.4. The entire 50 ml was inoculated into 500 ml Buffered Rich medium + 100 µg/ml ampicillin in a 2.8-L bottom-baffled Fernbach. Growth was continued at 37 °C and 250 rpm to an  $A_{590}$  = 0.6 to 1.4. Ten L of Buffered Rich medium + 100 µg/ml ampicillin in a 14-L vessel was inoculated with all 500 ml of culture. Temperature was maintained at 37 °C. Dissolved oxygen levels were controlled at >30% and pH at 7 +/- 0.3. At  $A_{590}$  = 1.5 to 2.0 the culture was induced by adding IPTG to 1 mM. Growth was continued for 2 hr at 37 °C. The vessel was chilled and harvested by centrifugation in a Sharples centrifuge. Cell paste was frozen and stored at -70 °C.

*Purification.* Frozen cells (20 g) were thawed on ice and suspended in 20 ml of 50 mM Tris-HCl (pH 8.0), 10% (w/v) sucrose, 0.002 mg/ml leupeptin, 0.002 mg/ml pepstatin A, 0.8 mg/ml benzamide, and 0.05 mg/ml Pefablock. Cells were disrupted by sonication (5 second bursts at 80% of the maximum setting alternated with 5 seconds off for 3 minutes). The extract was centrifuged at 27,000 X g for 30 minutes at 4° C and the supernatant was collected. The supernatant was loaded at 30 cm/hr onto a 20-ml column (1.6 x 10 cm) of Chelating Sepharose (Pharmacia) charged with  $\text{NiSO}_4$  and equilibrated with Buffer D (50 mM Tris-HCl (pH 7.5), 0.4 M NaCl, and 10 % (v/v) glycerol) + 5 mM Imidazol. The column was washed with 20 column volumes of Buffer D + 5 mM Imidazol at 30 cm/hr and developed with a 15-column volume linear gradient from Buffer D + 5 mM Imidazol to Buffer D + 450 mM Imidazol at 12 cm/hr. Fractions were analyzed by SDS PAGE. Peak fractions containing the Xis-His<sub>6</sub> protein were pooled and 0.5 M EDTA and 1 M DTT were added to final concentrations of 1 mM and 4 mM, respectively. The pool was then loaded at 38 cm/hr onto a 5.5 ml (1.0 x 7.0 cm) EMD-SO<sub>4</sub> (EM Separations) column

equilibrated in Buffer E (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10% (v/v) glycerol, and 4 mM DTT) + 0.4 M NaCl. The column was washed with 10 column volumes of Buffer E + 0.4 M NaCl at 76 cm/hr and developed with a 10-column volume linear gradient from Buffer E + 0.4 M NaCl to Buffer E + 2 M NaCl at 15 cm/hr. Fractions were analyzed by SDS PAGE. Xis-His<sub>6</sub> elutes in a broad peak at approximately 1.1- 1.8 M NaCl. The peak fractions containing Xis-His<sub>6</sub> were pooled. The pool was diluted with Buffer E to match the ionic strength of Buffer E + 0.2 M NaCl and loaded at 152 cm/hr onto a 1 ml (0.5 x 5.0 cm) Mono S (Pharmacia) column equilibrated in Buffer E + 0.2 M NaCl. The column was washed with 10 column volumes of Buffer E + 0.2 M NaCl. Xis-His<sub>6</sub> was eluted with 10 column volumes of Buffer E + 2.0 M NaCl at 61 cm/hr. Fractions were analyzed by SDS PAGE and the peak fractions containing Xis-His<sub>6</sub> were pooled. The pool was transferred to a 2,000 molecular weight cut off dialysis cassette (Pierce) and was dialyzed against 200 volumes of 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.05 mM EDTA, 50% (v/v) glycerol, and 1 mM DTT overnight at 4° C. The final sample was stored at -70° C.

#### *Cloning of S20*

The following two oligonucleotides were used to clone the S20 gene: TAT TAT TAT CAT ATG GCT AAT ATC AAA TCA GCT AAG (SEQ ID NO:5) and ATT ATT GGA TCC ATT AAG CCA GTT TGT TGA TCT (SEQ ID NO:6). The oligonucleotides were used to generate a 267-bp PCR product using *E. coli* chromosomal DNA as template. DNA was amplified (Materials and Methods section PCR) during 15 cycles composed of the following steps: 95 °C for 15 seconds, 50 °C for 15 seconds, and 67 °C for 30 seconds. The 267-bp PCR product was digested with *NdeI* and *BamHI* and cloned into the *NdeI* and *BamHI* sites of pTRCN2 (Figure 10) in *E. coli* DH10B. The resulting construct was called pTRCN2S20AA (Figure 13). The S20 gene is under control of a pTRC promoter. The DNA sequence of the S20 gene in pTRCN2S20AA was determined and found to match the published sequence, except as noted below. The initiation codon was changed from TTG to ATG

5 during cloning to enhance expression. pTRCN2S20AA was digested with *NdeI* and *BamHI* to generate a 267-bp fragment that was cloned into the *NdeI* and *BamHI* sites of pET12A (Novagen) in *E. coli* strain BL21DE3. The resulting  
10 construct was called pET12AS20AA (Figure 14). The S20 gene is under control of a T7 promoter.

### 15 *Purification of Recombinant S20*

S20 was purified from *E. coli* BL21DE3 bearing plasmid pET12AS20AA (see Materials and Methods section Cloning of S20).

20 *Growth of Cells.* Cells from a glycerol stock of BL21DE3 bearing plasmid pET12AS20AA were inoculated into 3 ml of LB broth containing 100 µg/ml ampicillin. This inoculum was diluted into LB broth + 100 µg/ml ampicillin 1:100 and the 300-ml culture was grown overnight at 30 °C. The  $A_{650}$  of the  
25 culture should not exceed 1.0. This culture was used to inoculate 10 flasks containing 500 ml each of Circlegrow (BIO 101) plus 100 µg/ml ampicillin plus 1 mM  $MgSO_4$ . Cells were grown at 37 °C until the  $A_{650}$  was 0.5 and expression of S20 was induced by the addition of IPTG to 0.5 mM. After growth at 37 °C for  
30 4 hours, cells were harvested by centrifugation at 4 °C and stored at -70 °C.

35 *Purification.* Frozen cells (10 g) were thawed on ice and suspended in 25 ml of 50 mM Tris-HCl (pH 7.5), 0.2 mM EDTA, 10% (v/v) glycerol, 0.2 mM DTT, 0.2 µg/ml leupeptin, and 1 mM PMSF. Cells were then disrupted by sonication (5 second bursts at 80% of the maximum setting alternated with  
40 5 seconds off for 1.5 minutes). NaCl (5.0 M) was then added to a final concentration of 0.67 M. The slurry was mixed by inverting the container and then placed on ice for 10 minutes. The mixture was centrifuged at 27,000 X g for 30 minutes at 4° C and the supernatant was collected. The supernatant was  
45 diluted with Buffer B (50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 10% (v/v) glycerol, 1 mM β-mercaptoethanol) to match the ionic strength of Buffer B + 0.3 M NaCl and then loaded at 30 cm/hr onto a 7.5 ml (1.8 x 3.7 cm) EMD-SO<sub>4</sub> (EM Separations) column equilibrated in Buffer B + 0.3 M NaCl. The column was  
50 washed with 10 column volumes of Buffer B + 0.3 M NaCl at 30 cm/hr and

developed with a 15-column volume linear gradient from Buffer E + 0.3 M NaCl to Buffer E + 1.8 M NaCl at 30 cm/hr. Fractions were analyzed by SDS PAGE. S20 eluted at approximately 0.9 M NaCl. The fractions containing the peak of S20 were pooled. The pool was transferred to a 2,000 molecular weight cut off dialysis cassette (Pierce) and dialyzed against 200 volumes of 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 0.05 mM EDTA, 50% (v/v) glycerol, and 1 mM DTT overnight at 4° C. The final sample was stored at -70° C.

#### *Integrative Recombination Gel Assay*

Reaction mixtures (10 µl final volume) for monitoring integrative recombination (defined as containing linearized *attB* and supercoiled *attP* DNA substrates) by agarose gel electrophoresis were incubated at 25 °C for 45 minutes. Reactions were initiated by adding 1 µl of Int or Int-His<sub>6</sub> (contained in 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 600 mM KCl, 2 mg/ml BSA, and 10% (v/v) glycerol) plus or minus potential stimulatory proteins to a mixture containing 20 mM Tris-HCl (pH 8.0), 5 mM spermidine, 50 µg/ml BSA, 125 ng linearized pBB105, 125 ng supercoiled pHN894, and 12.5 ng IHF. Incubation was stopped by raising the temperature to 70 °C for 10 minutes and then adding 2.5 µl of 25%(w/v) Ficoll 400, 0.5% (w/v) SDS, and 0.00625% (w/v) bromophenol blue. In some cases, reaction mixtures were treated with proteinase K (10 to 20 µg at 25 °C for 15 minutes). Samples were analyzed by electrophoresis in a 1% agarose minigel cast in 40 mM Tris-acetate (pH 8.3)- 1 mM EDTA (TAE) and 1 µg/ml ethidium bromide and run in TAE at 105 V for 30 minutes. Recombination activity is indicated by the appearance of a DNA band migrating at 10,201 bp. A unit of Int activity was defined as described (Nash, H.A. *Methods Enz.* 100: 210-216 (1983)).

#### *Excisive Recombination Gel Assay*

Reaction mixtures (10 µl final volume) for monitoring excisive recombination (defined as containing linearized *attL* and supercoiled *attR* DNA substrates) by agarose gel electrophoresis were incubated at 25 °C for 45 minutes.

Reactions were initiated by adding 1  $\mu$ l of Int or Int-His<sub>6</sub> (contained in 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 600 mM KCl, 2 mg/ml BSA, and 10% (v/v) glycerol) plus or minus potential stimulatory proteins to a mixture containing 20 mM Tris-HCl (pH 8.0), 5 mM spermidine, 50  $\mu$ g/ml BSA, 125 ng linearized pHN872, 125 ng supercoiled pHN868, 12.5 ng IHF, and 28 ng Xis or Xis-His<sub>6</sub>. Incubation was stopped by raising the temperature to 70 °C for 10 minutes and then adding 2.5  $\mu$ l of 25% (w/v) Ficoll 400, 0.5% (w/v) SDS, and 0.00625% (w/v) bromophenol blue. In some cases, reaction mixtures were treated with proteinase K (10 to 20  $\mu$ g at 25 °C for 15 minutes). Samples were analyzed by electrophoresis in a 1% agarose minigel cast in 40 mM Tris-acetate (pH 8.3)-1 mM EDTA (TAE) and 1  $\mu$ g/ml ethidium bromide and run in TAE at 105 V for 30 minutes. Recombination activity is indicated by the appearance of a DNA band migrating at 9,991 bp.

#### ***Integrative Recombination Colony-Forming Assay***

Reaction mixtures (20  $\mu$ l final volume) for monitoring integrative recombination (defined as containing linearized *attB* and supercoiled *attP* DNA substrates) by transformation of *E. coli* were incubated at 25 °C for 45 minutes. Reactions were initiated by adding 4  $\mu$ l of Int or Int-His<sub>6</sub> (contained in 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 200  $\mu$ g/ml BSA, and 50% (v/v) glycerol) plus or minus S20 to a mixture containing 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 2.5 mM spermidine, 0.25 mM EDTA, 200  $\mu$ g/ml BSA, 100 ng linearized pEZC7501, 100 ng supercoiled pEZ13835, and 10 ng IHF. Incubation was stopped by raising the temperature to 70 °C for 10 minutes. Proteinase K (4  $\mu$ g in 1  $\mu$ l) was added and after 10 minutes at 37 °C the mixture was centrifuged (14,000 rpm for 30 seconds). The mixture (1  $\mu$ l) was used to transform 100  $\mu$ l of ME DH5 $\alpha$  *E. coli* competent cells (LTI) in a sterile polypropylene tube on ice. After 30 minutes on ice, the tube was heat shocked in a 42 °C water bath for 45 seconds. The tube was then placed on ice for 2 minutes. S.O.C. medium (0.9 ml) was added to the tube, and the tube was placed in a shaker for 60 minutes at 37 °C and 225 rpm. Aliquots (10 and 100  $\mu$ l) of the



transformed cells were spread on separate agar plates prepared in LB medium + 100 µg/ml kanamycin, and the plates were incubated at 37 °C for 16 to 24 hours. Kanamycin-resistant colonies arise only as the result of an integrative recombination event.

#### ***Excisive Recombination Colony-Forming Assay***

Reaction mixtures (20 µl final volume) for monitoring excisive recombination (defined as containing linearized *attR* and supercoiled *attL* DNA substrates) by transformation of *E. coli* were incubated at 25 °C for 45 minutes. Reactions were initiated by adding 4 µl of Int or Int-His<sub>6</sub> (contained in 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 200 µg/ml BSA, and 50% (v/v) glycerol) plus or minus S20 to a mixture containing 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 2.5 mM spermidine, 0.25 mM EDTA, 200 µg/ml BSA, 100 ng linearized pEZC8402, 100 ng supercoiled pEZ11104, 12.5 ng IHF, and 28 ng Xis or Xis-His<sub>6</sub>. Incubation was stopped by raising the temperature to 70 °C for 10 minutes. Proteinase K (4 µg in 1 µl) was added and after 10 minutes at 37 °C the mixture was centrifuged (14,000 rpm for 30 seconds). A portion of the reaction mixture (10.5 µl) was diluted with 89.5 µl of T<sub>10</sub>E<sub>1</sub>. The diluted mixture (1 µl) was used to transform 100 µl of ME DH5α *E. coli* competent cells (LTI) in a sterile polypropylene tube on ice. After 30 minutes on ice, the tube was heat shocked in a 42 °C water bath for 45 seconds. The tube was then placed on ice for 2 minutes. S.O.C. medium (0.9 ml) was added to the tube, and the tube was placed in a shaker for 60 minutes at 37 °C and 225 rpm. Aliquots (10 and 100 µl) of the transformed cells were spread on separate agar plates prepared in LB medium + 100 µg/ml ampicillin, and the plates were incubated at 37 °C for 16 to 24 hours. Ampicillin-resistant colonies arise only as the result of an excisive recombination event.

**RESULTS****PART I: Restoration of Integrase Activity by Mixing with Cell Extract Components**

*Restoration of Int Activity by Column Fractions.* Purification of Int overexpressed in *E. coli* involved differential salt precipitation followed by phosphocellulose and hydroxyapatite chromatography (Materials and Methods). When we attempted to purify native Int by this procedure, we found that Int integrative recombination activity (determined as described in Materials and Methods section, Integrative Recombination Gel Assay) was maintained through the phosphocellulose chromatography step, but was lost during the final hydroxyapatite chromatography step. No activity was found in any hydroxyapatite column fraction. This was not caused by loss of Int protein during chromatography, since SDS-PAGE analysis of the hydroxyapatite fractions revealed the presence of a single protein of molecular weight 40 KDa, consistent with the bound protein being Int. Fractions containing the peak of the 40-KDa protein were pooled and the pool was assayed for integrative recombination activity. As the results shown in Table 2 indicate, no activity was observed.

**TABLE 2: SUMMARY OF PURIFICATION OF NATIVE Int**

Purification Step	Total Units	Total Protein (mg)	Specific Activity (U/mg)
Crude Extract	228,000	1,294	176
Differential salt precipitation	67,000	153	441
Phosphocellulose	21,000	6.7	3,134
Hydroxyapatite	0	0.2	--
Hydroxyapatite + stimulatory protein(s)	~30,000	0.2	~150,000

Examination of the proteins in the phosphocellulose pool by SDS PAGE revealed the presence of Int (40 KDa) and a number of smaller proteins (at least six) in the 5 to 17 KDa range. *E. coli* DNA binding proteins that stimulate Int activity, such as HU, fall in this small size range (Segall, A.M. et. al, *EMBO J.* 13: 4536-4548 (1994)). We therefore hypothesized that this preparation of Int required additional component(s) for activity beyond the IHF already present in recombination reaction mixtures (Materials and Methods). Further, the chromatography results suggested that this component(s) coeluted with Int from phosphocellulose, but was not bound by hydroxyapatite. To test this hypothesis, the material from the original phosphocellulose pool that did not bind to hydroxyapatite was fractionated again on a phosphocellulose column. Samples from fractions from this column were assayed for ability to restore integrative recombination activity to the inactive Int pooled from the hydroxyapatite column. We found that fractions eluting from the phosphocellulose column at around 1.0 M KCl contained a component(s) that restored recombination activity to the inactive Int (Figure 15). The fractions with the greatest stimulatory activity (Fraction Numbers 15 through 18 in Figure 15) were used for further characterization. Unit assay of the Int hydroxyapatite pool in the integrative recombination assay in the presence of an optimal amount of this stimulatory material indicated that greater than 100% of the Int activity present in the phosphocellulose pool was present in the hydroxyapatite pool when the stimulatory component(s) was present in the unit assay (Table 2).

*Characterization of the Stimulatory Component(s).* SDS PAGE analysis of the stimulatory fractions from the second phosphocellulose column showed multiple small protein bands, two of which appeared similar in size to the subunits of authentic IHF (Figure 15). On the chance that the concentration of IHF being used in the integrative recombination gel assay was not optimal, a careful titration of IHF was carried out with inactive Int in the presence and absence of stimulatory material from the phosphocellulose column. We found that no amount of IHF alone, from 12.5 to 1,250 ng, stimulated inactive Int. In

contrast, the combination of IHF at 12.5 ng and the component(s) from the phosphocellulose column did restore Int activity.

Treatment of the stimulatory component(s) with DNase I or RNase A did not diminish ability to stimulate Int. Placing the component(s) in a boiling water bath for 30 minutes also had no effect. However, treatment with proteinase K eliminated ability to stimulate, indicating the stimulatory component(s) was protein that could withstand high temperature.

## **PART II: *Purification and Identification of the Stimulatory Proteins***

*Purification from a Side Fraction.* We wished to identify the protein(s) in extracts of *E. coli* expressing native Int that stimulate its recombinase activity. Purification was monitored by detecting the presence of Int stimulatory protein using the integrative recombination gel assay (Materials and Methods) and inactive Int, purified as just described (Materials and Methods section Purification of Native Int and Results section PART I: Restoration of Integrase Activity by Mixing with Cell Extract Components). We took advantage of the fact that extracts could be heated to boiling water temperatures without affecting adversely the stimulatory activity. Heating served several purposes. First, any active Int present during early purification steps would be irreversibly inactivated, eliminating interference in the gel recombination assay. Second, many *E. coli* proteins in crude extracts precipitate at high temperature; thus heating facilitates purification of those proteins that remain soluble.

The side fractions generated early in the native Int purification (Materials and Methods section Purification of Native Int) were heated to 100 °C, clarified by centrifugation, and assayed for ability to stimulate inactive Int. The supernatant from the first high speed centrifugation in the differential salt precipitation step was found to have the most stimulatory activity. Using this supernatant as starting material, a stimulatory protein was purified as described in Materials and Methods section Purification of Stimulatory Protein as a Side Fraction of a Native Int Preparation. A near homogeneous 11-KDa protein was

5 purified after two column chromatography steps (Figure 16) that stimulated inactive Int in the gel recombination assay (Figure 17).

10 The 11-KDa protein was sent to the HHMI Biopolymer Laboratory, W.M. Keck Foundation, for amino terminal amino acid sequence analysis (Materials and Methods section Amino-Terminal Amino Acid Sequence Analysis of Stimulatory Proteins). The sequence was found to be Ala-Asn-Ile-Lys-Ser-Ala-  
15 Lys-Lys-Arg-Ala-Ile-Gln-Ser-Glu (SEQ ID NO:7). Search of the GenBank sequence data base revealed that this sequence matches amino acids 2 through 15 of *E. coli* 30S ribosomal protein S20 (Mackie, G.A. *J. Biol. Chem.* 256:8177-8182 (1981)). S20 is a very basic protein of 86 amino acids. In *E. coli*, S20  
20 appears to be involved in association of the 30S ribosomal subunit with the 50S subunit and in formation of the 30S subunit translation initiation complex with fMet-tRNA and mRNA (Gotz, F. *et. al Biochim. Biophys. Acta* 1050: 93-97 (1990)). The gene for S20 was cloned, overexpressed, and purified (see Materials  
25 and Methods sections Cloning of S20 and Purification of Recombinant S20). The ability of recombinant S20 to stimulate Int was tested (see Results, PART III).

30 *Purification from Total Cell Extract.* Since we were able to identify one small, heat resistant, nucleic acid binding protein in extracts of *E. coli* that stimulates Int activity, we asked if there were others. Using the gel recombination  
20 assay with inactive Int to assay for stimulation of Int, and starting with total *E. coli* cell extract, purification of stimulatory activity was repeated (see Materials  
35 and Methods section Purification of Stimulatory Proteins from Cells Producing Native Int). Again, phosphocellulose followed by Mono S chromatography was used to fractionate heated *E. coli* extract. A second stimulatory protein was  
40 identified that migrated on SDS PAGE slightly faster than S20 (Figure 18). This protein was also sent to the HHMI Biopolymer Laboratory, W.M. Keck Foundation, for sequence analysis. The sequence was found to be Ala-His-Lys-  
45 Lys-Ala-Gly-Gly-Ser-Thr-Arg-Asn (SEQ ID NO:8). Search of the GenBank sequence data base revealed that this sequence matches amino acids 2 through 12 of *E. coli* 50S ribosomal protein L27 (Jeong, J.H. *et. al, DNA Seq.* 4: 59-67  
30 (1993)). L27 is a very basic protein of 85 amino acids. The proteins in fraction  
50

18 (lanes A and B of Figure 18), the primary constituent of which was L27, were tested for ability to stimulate Int in the integrative recombination gel assay. Figure 19 shows that these proteins stimulated Int in the recombination assay. However, 10 times more L27 than S20 was required to produce a discernible recombinant DNA product.

### PART III: Cloning of S20 and Demonstration of Activity

*Cloning, Overexpression, and Purification of rS20.* We cloned the gene for S20 from *E. coli* DNA under control of a T7 promoter using PCR (see Materials and Methods section Cloning of S20). The recombinant S20 was highly overexpressed and easily purified by EMD-SO<sub>4</sub> chromatography (see Materials and Methods section Purification of Recombinant S20). Approximately 110 mg of near homogeneous recombinant S20 (Figure 20) was purified from 9 g of *E. coli*.

*Characterization of rS20.* Recombinant S20 stimulated integrative and excisive  $\lambda$  recombination catalyzed by native Int as determined by gel assay (Figure 19), and recombinant S20 also stimulated both integrative and excisive  $\lambda$  recombination catalyzed by recombinant Int-His<sub>6</sub> as determined both by gel assay (Figure 21) and colony-forming assay (Tables 3 and 4). These results confirmed those obtained with native S20; that is, recombinant S20 stimulates the recombinase activity of Int.

**TABLE 3: STIMULATION OF INT-HIS<sub>6</sub> BY RECOMBINANT S20 IN AN INTEGRATIVE RECOMBINATION COLONY-FORMING ASSAY\***

Amt. of Recombinant S20 (ng)	Number of Colonies Formed
0	35
313	82
625	255
1,250	233
2,500	5

\*See Materials and Methods for details of assay. All reaction mixtures contained 176 ng Int-His<sub>6</sub> and 10 ng IHF.

**TABLE 4: STIMULATION OF INT-HIS<sub>6</sub> BY RECOMBINANT S20 IN AN EXCISIVE RECOMBINATION COLONY-FORMING ASSAY\***

Amt. of Recombinant S20 (ng)	Number of Colonies Formed
0	9
158	86
313	1,392
625	83
1,250	23

\*See Materials and Methods for details of assay. All reaction mixtures contained 176 ng Int-His<sub>6</sub>, 12.5 ng IHF, and 28 ng Xis-His<sub>6</sub>.

The order of addition of S20 and Int to a reaction appears to be important. Int should be mixed with S20 and the proteins added as a mixture to IHF and DNAs to obtain greatest stimulation of integrative recombination. If S20 is added before Int, or if Int is added before S20, less stimulation is observed. These results suggest S20 might be binding to Int and producing some kind of physical change that enhances its recombinase activity. Gel shift assays show that S20 binds to the DNA substrates in recombination assays. Thus, treatment of recombination assay mixtures containing large amounts of S20 with proteinase

K is necessary to avoid trapping of DNA in wells during agarose gel electrophoresis. Titration of the amount of S20 versus number of recombinants obtained in both the integrative (Table 3) and excisive (Table 4) colony-forming recombination assay demonstrated rather sharp optima for amount of S20, particularly in the excisive reaction. The molar ratios of S20 to DNA nucleotides at the optimal amounts of S20 in these assays were 5 to 10 nucleotides per S20 molecule in the integrative reaction and 25 nucleotides per S20 molecule in the excisive reaction. We speculate that the binding footprint for a protein of the size of S20 (~10 kDa) functioning as a monomer is in the range of 5 to 10 nucleotides per molecule of protein. The optimum for the integrative reaction falls in this range, suggesting that for optimal stimulation of the integrative recombination sufficient S20 must be present to coat the DNA. Making the same assumptions, it would appear that in the excisive reaction, the presence of sufficient S20 to coat the DNA inhibits the reaction. In any case, binding of S20 to DNA is probably also exerting an effect on the efficiency of the recombination reaction, just as does the binding of other small nonspecific DNA binding proteins (Segall, A.M. *et. al*, *EMBO J.* 13: 4536-4548 (1994)).

#### **PART IV. Integrative Recombination Activity of Int and Int-His<sub>6</sub>**

We have completed three purifications of native  $\lambda$  Int following a modification (Materials and Methods) of the published purification procedure (Nash, H.A. *Methods Enz.* 100: 210-216 (1983)), and a much larger number of purifications of cloned Int-His<sub>6</sub> by a simpler procedure (Materials and Methods). As a result of characterization of the integrative recombinase activity of these preparations using the gel assay (see Materials and Methods section Integrative Recombination Gel Assay), we can draw several general conclusions about the activity of Int in the presence and absence of S20. First, preparations of Int or Int-His<sub>6</sub> that are nearly homogeneous and that are kept in a high salt (0.6 M KCl), low glycerol (10%) buffer during the final purification step (as recommended in the published purification procedure), and then are stored in that buffer in the



5 presence or absence of BSA at -70 °C, generally have reduced Int recombinase  
activity. But with all preparations tested, the activity can be increased by mixing  
10 Int with S20 before addition to an assay. We have found, however, that the  
activities of preparations of Int in the high salt buffer which appear lower can be  
5 increased to a certain extent by diluting the preparation in a low salt buffer  
(0.05 M KCl) before assay or more preferably by dialyzing the preparation into  
15 a buffer containing low salt (0.05 to 0.1 M KCl) and 50% (v/v) glycerol. Such  
preparations can then be stored at -20 °C or -70 °C. Furthermore, regardless of the  
level of recombinase activity these preparations have by themselves before or  
10 after dialysis, addition of appropriate amounts of S20 stimulates that activity.

### Conclusions

25 Taken together, these results demonstrate that at least two *E. coli*  
ribosomal proteins, S20 and L27, and possibly a third *E. coli* ribosomal protein,  
15 S15, stimulate  $\lambda$  Int-mediated recombination *in vitro*. In addition, purified  
preparations of  $\lambda$  Int that appear to be inactive in a  $\lambda$  recombination system can  
be restored to activity by the addition of S20.

### 20 Example 2: *Stimulation of Integrase Recombination by other E. coli* 35 *Ribosomal Proteins*

In addition to S20 and L27, other *E. coli* ribosomal proteins may stimulate  
the activity of recombination systems, particularly the  $\lambda$  Int system. In particular,  
40 25 *E. coli* ribosomal proteins that are basic and are about 14 kilodaltons or less in  
size are used to stimulate the activity of prokaryotic recombination systems.  
Such ribosomal proteins that may be used are shown in Table 5:

**TABLE 5: Additional Ribosomal Proteins for Use in Stimulating Recombination Activity**

Ribosomal Protein	No. of Basic Residues (% of Total)	No. of Total Residues	Molecular Weight (Daltons)
S10	17 (16.5%)	103	11,736
S14	23 (23.7%)	97	11,063
S15	16 (18.4%)	87	10,001
S16	14 (17.1%)	82	9,191
S17	16 (19.3%)	83	9,573
S18	17 (23.0%)	74	8,896
S19	19 (20.9%)	91	10,299
S21	23 (32.9%)	70	8,369
L21	17 (16.5%)	103	11,565
L23	21 (21.2%)	99	11,013
L24	22 (21.4%)	103	11,185
L25	17 (18.1%)	94	10,694
L28	18 (23.4%)	77	8,875
L29	12 (19.0%)	63	7,274
L30	10 (17.2%)	58	6,411
L31	12 (19.4%)	62	6,971
L32	11 (19.6%)	56	6,315
L33	15 (27.8%)	54	6,255
L34	14 (30.4%)	46	5,381

These ribosomal proteins are isolated from natural sources as generally described above for S20 and L27 and as discussed in *Ann. Rev. Biochem* 51:155 (1982), *Ann. Rev. Biochem.* 52:35 (1983), *Ann. Rev. Biochem* 53:75 (1984), and *Ann. Rev. Biochem* 66:679 (1997). Alternatively, the ribosomal proteins are prepared by recombinant DNA methodologies as generally outlined above for the

5 production of S20 and Xis. Isolated ribosomal proteins are used to stimulate  
recombination activity, particularly that of Int, by including one or more of them  
10 in the compositions of the invention as described above for S20 and L27, and  
these compositions are used in integrative and excisive recombination assays, and  
5 in the recombinational cloning methods of the invention, as generally outlined in  
Example 1 for S20. In addition, ribosomal proteins corresponding to those  
15 described herein may be used in accordance with the invention. For example,  
ribosomal proteins from other prokaryotic sources, and from eukaryotic sources  
(*e.g.*, yeast, fungi, animals (including mammals such as humans), plants, and the  
10 like) may be used in the methods and compositions of the invention.

20 Having now fully described the present invention in some detail by way  
of illustration and example for purposes of clarity of understanding, it will be  
25 obvious to one of ordinary skill in the art that the same can be performed by  
15 modifying or changing the invention within a wide and equivalent range of  
conditions, formulations and other parameters without affecting the scope of the  
invention or any specific embodiment thereof, and that such modifications or  
30 changes are intended to be encompassed within the scope of the appended claims.

20 All publications, patents and patent applications mentioned in this  
specification are indicative of the level of skill of those skilled in the art to which  
35 this invention pertains, and are herein incorporated by reference to the same  
extent as if each individual publication, patent or patent application was  
specifically and individually indicated to be incorporated by reference.

**Claims**

5

10

15

20

25

30

35

40

45

50

55

## WHAT IS CLAIMED IS:

1. A composition for use in cloning or subcloning one or more desired nucleic acid molecules by recombinational cloning, comprising an effective amount of at least one ribosomal protein and an effective amount of at least one recombination protein.

2. The composition of claim 1, wherein said ribosomal protein is a prokaryotic ribosomal protein.

3. The composition of claim 1, wherein said ribosomal protein is an *Escherichia coli* ribosomal protein.

4. The composition of claim 1, wherein said ribosomal protein is a basic ribosomal protein.

5. The composition of claim 1, wherein said ribosomal protein has a molecular weight of less than about 14 kilodaltons.

6. The composition of claim 3, wherein said *E. coli* ribosomal protein is selected from the group of *E. coli* ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31, L32, L33 and L34.

7. The composition of claim 3, wherein said *E. coli* ribosomal protein is S20.

8. The composition of claim 3, wherein said *E. coli* ribosomal protein is L27.

5 9. The composition of claim 3, wherein said *E. coli* ribosomal protein is S15.

10 10. The composition of claim 1, wherein said recombination protein  
5 is a prokaryotic recombination protein.

15 11. The composition of claim 1, wherein said recombination protein is selected from the group consisting of Int, Cre, FLP, Xis, IHF and HU, and combinations thereof.

20 12. The composition of claim 1, wherein said recombination protein is Int.

25 13. The composition of claim 1, further comprising one or more  
15 nucleic acid molecules selected from the group consisting of one or more Insert Donor molecules, one or more Vector Donor molecules, one or more Cointegrate molecules, one or more Product molecules and one or more Byproduct molecules.  
30

20 14. A method for cloning or subcloning one or more desired nucleic acid molecules comprising

- 35 (a) forming a combination by combining *in vitro* or *in vivo*
- 40 (i) one or more Insert Donor molecules comprising one or more desired nucleic acid segments flanked by at least two recombination sites, wherein said recombination sites do  
25 not substantially recombine with each other;
  - (ii) one or more Vector Donor molecules comprising at least two recombination sites, wherein said recombination sites  
45 do not substantially recombine with each other;
  - (iii) an effective amount of at least one recombination protein;  
30 and
  - 50 (iv) an effective amount of at least one ribosomal protein; and
- 55

- 5 (b) incubating said combination under conditions sufficient to transfer  
one or more of said desired segments into one or more of said  
10 Vector Donor molecules, thereby producing one or more desired  
Product nucleic acid molecules.

15 15. The method of claim 14, further comprising:

- 15 (c) forming a combination by combining *in vitro* or *in vivo*

(i) one or more of said Product molecules comprising said  
desired segments flanked by two or more recombination  
10 sites, wherein said recombination sites do not substantially  
recombine with each other;

(ii) one or more different Vector Donor molecules comprising  
two or more recombination sites, wherein said  
25 recombination sites do not substantially recombine with  
each other;

(iii) an effective amount of at least one recombination protein;  
and

(iv) an effective amount of at least one ribosomal protein; and

- (d) incubating said combination under conditions sufficient to transfer  
20 one or more of said desired segments into one or more different  
35 Vector Donor molecules, thereby producing one or more different  
Product molecules.

40 16. The method of claim 14, wherein said ribosomal protein is a  
25 prokaryotic ribosomal protein.

45 17. The method of claim 15, wherein said ribosomal protein is a  
prokaryotic ribosomal protein.

30 18. The method of claim 14, further comprising incubating said  
50 different Product molecules with one or more different Vector Donor molecules

under conditions sufficient to transfer one or more of said desired segments into said different Vector Donor molecules.

19. A method for cloning or subcloning desired nucleic acid molecules comprising

- a) forming a combination by combining *in vitro* or *in vivo*
  - i) one or more Insert Donor molecules comprising one or more nucleic acid segments flanked by two or more recombination sites, wherein said recombination sites do not substantially recombine with each other;
  - ii) two or more different Vector Donor molecules comprising two or more recombination sites, wherein said recombination sites do not substantially recombine with each other;
  - iii) an effective amount of at least one recombination protein; and
  - iv) an effective amount of at least one ribosomal protein; and
- b) incubating said combination under conditions sufficient to transfer one or more of said desired segments into said different Vector Donor molecules, thereby producing two or more different Product molecules.

20. The method of claim 19, wherein said ribosomal protein is a prokaryotic ribosomal protein.

21. The method of claim 14, wherein said ribosomal protein is an *Escherichia coli* ribosomal protein.

22. The method of claim 14, wherein said ribosomal protein is a basic ribosomal protein.



5                   23.     The method of claim 14, wherein said ribosomal protein has a  
molecular weight of less than about 14 kilodaltons.

10                   24.     The method of claim 21, wherein said *E. coli* ribosomal protein is  
5     selected from the group of *E. coli* ribosomal proteins consisting of S10, S14, S15,  
S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31,  
15     L32, L33 and L34.

                  25.     The method of claim 21, wherein said ribosomal protein is S20.

10                   26.     The method of claim 21, wherein said ribosomal protein is L27.

20                   27.     The method of claim 21, wherein said ribosomal protein is S15.

25                   28.     The method of claim 19, wherein said recombination protein is a  
15     prokaryotic recombination protein.

30                   29.     The method of claim 14, wherein said recombination protein is  
selected from the group consisting of Int, Cre, FLP, Xis, IHF, and HU, and  
20     combinations thereof.

35                   30.     The method of claim 14, wherein said recombination protein is Int.

40                   31.     A method for recombinational cloning of one or more desired  
25     nucleic acid molecules comprising

- (a)     forming a mixture by mixing one or more of said desired nucleic  
acid molecules with one or more vectors and with the composition of claim 1; and  
45                   (b)     incubating said mixture under conditions sufficient to transfer said  
one or more desired nucleic acid molecules into one or more of said vectors.

5                   32.    The method of claim 31, wherein said desired nucleic acid  
                  molecules are derived from genomic DNA.

10                   33.    The method of claim 31, wherein said desired nucleic acid  
5                   molecules are derived from cDNA.

15                   34.    The method of claim 31, wherein said desired nucleic acid  
                  molecules are produced by chemical synthesis.

20                   35.    The method of claim 31, wherein said desired nucleic acid  
10                   molecules are produced by amplification.

25                   36.    The method of claim 31, wherein said vector is a prokaryotic or  
                  eukaryotic vector.

15                   37.    The method of claim 36, wherein said eukaryotic vector  
30                   propagates and/or replicates in yeast cells, plant cells, fish cells, eukaryotic cells,  
                  mammalian cells, and/or insect cells.

20                   38.    The method of claim 31, wherein said prokaryotic vector  
35                   propagates and/or replicates in bacteria of the genera *Escherichia*, *Salmonella*,  
                  *Bacillus*, *Streptomyces* or *Pseudomonas*.

40                   39.    The method of claim 38, wherein said prokaryotic vector  
25                   propagates and/or replicates in *E. coli*.

45                   40.    A method for enhancement of recombinational cloning,  
                  comprising contacting a nucleic acid molecule with one or more ribosomal  
                  proteins and with one or more recombination proteins.

30

50

55

5 41. The method of claim 40, wherein said ribosomal protein is a prokaryotic ribosomal protein.

10 42. The method of claim 40, wherein said ribosomal protein is an  
5 *Escherichia coli* ribosomal protein.

15 43. The method of claim 40, wherein said ribosomal protein is a basic ribosomal protein.

20 44. The method of claim 40, wherein said ribosomal protein has a molecular weight of less than about 14 kilodaltons.

25 45. The method of claim 42, wherein said *E. coli* ribosomal protein is selected from the group of *E. coli* ribosomal proteins consisting of S10, S14, S15,  
15 S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31, L32, L33 and L34.

30 46. The method of claim 42, wherein said ribosomal protein is S20.

20 47. The method of claim 42, wherein said ribosomal protein is L27.

35 48. The method of claim 42, wherein said ribosomal protein is S15.

40 49. The method of claim 40, wherein said recombination protein is a prokaryotic recombination protein.  
25

45 50. The method of claim 40, wherein said recombination protein is selected from the group consisting of Int, Cre, FLP, Xis, IHF, and HU, and combinations thereof.

30 51. The method of claim 40, wherein said recombination protein is Int.  
50

52. A DNA molecule produced by the method of claim 31.

53. The DNA molecule of claim 52, wherein said DNA molecule is an isolated DNA molecule.

54. A host cell comprising the DNA molecule of claim 52.

55. A kit for use in recombinational cloning of a nucleic acid molecule, said kit comprising at least one ribosomal protein and at least one recombination protein.

56. The kit of claim 55, wherein said ribosomal protein is a prokaryotic ribosomal protein.

57. The kit of claim 55, wherein said ribosomal protein is an *Escherichia coli* ribosomal protein.

58. The kit of claim 57, wherein said *E. coli* ribosomal protein is selected from the group of *E. coli* ribosomal proteins consisting of S10, S14, S15, S16, S17, S18, S19, S20, S21, L21, L23, L24, L25, L27, L28, L29, L30, L31, L32, L33 and L34.

59. The kit of claim 57, wherein said ribosomal protein is S20.

60. The kit of claim 57, wherein said ribosomal protein is L27.

61. The kit of claim 57, wherein said ribosomal protein is S15.

62. The kit of claim 55, wherein said recombination protein is a prokaryotic recombination protein.

5

63. The kit of claim 55, wherein said recombination protein is selected from the group consisting of Int, Cre, FLP, Xis, IHF, and HU.

10

64. The kit of claim 55, wherein said recombination protein is Int.

5

15

20

25

30

35

40

45

50

55




Figure 1




FIGURE 2




FIGURE 3






FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10




FIGURE 11






Figure 12




FIGURE 13.




FIGURE 14




FIGURE 15




FIGURE 16



FIGURE 17




FIGURE 18



FIGURE 19






FIGURE 20




FIGURE 21

-1-

## SEQUENCE LISTING

&lt;110&gt; Life Technologies, Inc.

&lt;120&gt; Compositions and Methods for Recombinational Cloning of Nucleic Acid Molecules

&lt;130&gt; 0942.464PC01

&lt;140&gt; (To be assigned)

&lt;141&gt; 1999-11-12

&lt;150&gt; US 60/108,324

&lt;151&gt; 1998-11-13

&lt;160&gt; 8

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 45

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic oligonucleotide

&lt;400&gt; 1

tattattatc atatgggacg acgtcgaagt catgagcgcc gggat

45

&lt;210&gt; 2

&lt;211&gt; 58

&lt;212&gt; DNA

&lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; Description of artificial sequence: synthetic oligonucleotide

&lt;400&gt; 2

attattaagc ttattaatgg tgatgatggt gatgtttgat ttcaattttg tcccactc

58

&lt;210&gt; 3

&lt;211&gt; 33

&lt;212&gt; DNA

<213> Artificial sequence

<220>

<223> Description of artificial sequence: synthetic oligonucleotide

<400> 3

tattattatc atatgtactt gacacttcag gag

33

<210> 4

<211> 55

<212> DNA

<213> Artificial sequence

<220>

<223> Description of artificial sequence: synthetic oligonucleotide

<400> 4

attattaagc ttattaatgg tgatgatggt gatgtgactt cgccttcctc ccatt

55

<210> 5

<211> 36

<212> DNA

<213> Artificial sequence

<220>

<223> Description of artificial sequence: synthetic oligonucleotide

<400> 5

tattattatc atatggctaa tatcaaatca gctaag

36

<210> 6

<211> 33

<212> DNA

<213> Artificial sequence

<220>

<223> Description of artificial sequence: synthetic oligonucleotide

<400> 6

attattggat ccattaagcc agtttggtga tct

33

<210> 7

-3-

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Escherichia coli

&lt;400&gt; 7

Ala Asn Ile Lys Ser Ala Lys Lys Arg Ala Ile Gln Ser Glu

1

5

10

&lt;210&gt; 8

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Escherichia coli

&lt;400&gt; 8

Ala His Lys Lys Ala Gly Gly Ser Thr Arg Asn

1

5

10

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/26871

## A. CLASSIFICATION F SUBJECT MATTER

IPC(7) :A61K 35/00; C12N 15/00, 9/16, 1/20, 1/00; C07H 21/02  
US CL :424/93.1; 435/320.1, 172.3, 196, 252.3; 935/14, 29; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1; 435/320.1, 172.3, 196, 252.3; 935/14, 29; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VENKATESH ET. AL.. Ribosomal Protein S1 and NusA Protein Complexed to Recombination Protein B of phage $\gamma$ . Journal of Bacteriology, March 1993, Vol. 175, No 6, see pages 1844-1846.	1-5
X	BRUCKNER ET AL. The histone-like H protein of Escherichia coli is ribosomal protein S3, Nucleic Acids Research 1989, Vol. 17, No. 8, see pages 3145-3161	1-5



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	* Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* B* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 FEBRUARY 2000

Date of mailing of the international search report

23 MAR 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PADMA BASAR

Telephone No. (703) 308-8886

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/26871

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

WEST, STN, DIALOG, BIOSIS, MEDLINE, SCI SEARCH, LIFE SCIENCE, EMBASE, PASCAL, CONFERENCE PAER INDEX, WPIDS.

search terms: Ribosomal protein, recombination protein, clone subclone, cre,fp, xis, ihf, hu.

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claim(s) 1-13, 14-39 AND 40-51, drawn to A protein, method of making and method of use.

Group II, claim(s) 52-54, drawn to a another composition which a DNA and host cell.

Group III, claim(s) 55-64, drawn to a Kit.

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I is directed to a protein, method for producing the protein and method of using that protein which is the first product and first method of making, and using the product. The special technical feature is the protein and its use. Groups II and III are drawn to structurally different products, DNA and KIT which do not require each other for their practice and do not share the same or a corresponding technical feature. Note that PCT Rule 13 does not provide for multiple products or methods within a single application. Since the special technical feature of the Group I invention is not present in the Groups II-III claims, a unity of invention is lacking.